

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

Nature Reviews Drug Discovery

1, 287-299

DOI: [10.1038/nrd772](https://doi.org/10.1038/nrd772)

Citation Report

#	ARTICLE	IF	CITATIONS
1	An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 17095-17100.	7.1	356
2	IKK β and Phosphatidylinositol 3-Kinase/Akt Participate in Non-pathogenic Gram-negative Enteric Bacteria-induced RelA Phosphorylation and NF- κ B Activation in Both Primary and Intestinal Epithelial Cell Lines. Journal of Biological Chemistry, 2002, 277, 38168-38178.	3.4	152
3	Histone deacetylase inhibitors: from target to clinical trials. Expert Opinion on Investigational Drugs, 2002, 11, 1695-1713.	4.1	213
4	Emerging cancer-targeted therapies. Pediatric Clinics of North America, 2002, 49, 1339-1368.	1.8	7
5	Expeditious synthesis of aziridine-based cofactor mimics. Tetrahedron, 2002, 58, 6019-6026.	1.9	17
6	The Molecular Perspective: Histone Deacetylase. Stem Cells, 2003, 21, 620-621.	3.2	7
7	Heterocyclic ketones as inhibitors of histone deacetylase. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3909-3913.	2.2	55
8	Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. Cellular and Molecular Life Sciences, 2003, 60, 1990-1997.	5.4	71
9	Histone deacetylase inhibitors in cancer therapy. Cancer Cell, 2003, 4, 13-18.	16.8	451
10	Nonisotopic substrate for assaying both human zinc and NAD ⁺ -dependent histone deacetylases. Analytical Biochemistry, 2003, 319, 42-48.	2.4	84
11	Multidimensional Chemical Genetic Analysis of Diversity-Oriented Synthesis-Derived Deacetylase Inhibitors Using Cell-Based Assays. Chemistry and Biology, 2003, 10, 383-396.	6.0	190
12	β -Keto amides as inhibitors of histone deacetylase. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3331-3335.	2.2	79
13	Overview of the clinical efficacy of investigational anticancer drugs. Journal of Internal Medicine, 2003, 253, 46-75.	6.0	75
14	Regulation of microglial inflammatory response by histone deacetylase inhibitors. Journal of Neurochemistry, 2003, 87, 407-416.	3.9	104
16	Cancer epigenetics. Oncogene, 2003, 22, 6479-6483.	5.9	253
17	Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene, 2003, 22, 7305-7315.	5.9	297
19	Discovery of (Aryloxopropenyl)pyrrolyl Hydroxyamides as Selective Inhibitors of Class IIa Histone Deacetylase Homologue HD1-A. Journal of Medicinal Chemistry, 2003, 46, 4826-4829.	6.4	63
20	Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochemical Journal, 2003, 370, 737-749.	3.7	2,671

#	ARTICLE	IF	CITATIONS
21	Histone Deacetylase Inhibitors: Assays to Assess Effectiveness In Vitro and In Vivo. <i>Methods in Enzymology</i> , 2003, 376, 199-205.	1.0	15
22	Recent progress in the development of assays suited for histone deacetylase inhibitor screening. <i>Molecular Genetics and Metabolism</i> , 2003, 80, 138-147.	1.1	33
23	3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 1. Design, Synthesis, Biological Evaluation, and Binding Mode Studies Performed through Three Different Docking Procedures. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 512-524.	6.4	113
24	Valproate administration to mice increases histone acetylation and 5-lipoxygenase content in the hippocampus. <i>Neuroscience Letters</i> , 2003, 345, 141-143.	2.1	52
25	Cell-cycle dysregulation and anticancer therapy. <i>Trends in Pharmacological Sciences</i> , 2003, 24, 139-145.	8.7	294
26	Chromatin remodeling and human disease. <i>Current Opinion in Genetics and Development</i> , 2003, 13, 246-252.	3.3	70
27	Hallmarks of radiation carcinogenesis: ignored concepts. <i>International Congress Series</i> , 2003, 1258, 31-36.	0.2	3
28	Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype. <i>Drug Resistance Updates</i> , 2003, 6, 247-256.	14.4	39
29	Methylation and acetylation in nervous system development and neurodegenerative disorders. <i>Ageing Research Reviews</i> , 2003, 2, 329-342.	10.9	113
30	Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 5097-5116.	6.4	528
31	N-Hydroxy-3-phenyl-2-propenamides as Novel Inhibitors of Human Histone Deacetylase with in Vivo Antitumor Activity: Discovery of (2E)-N-Hydroxy-3-[4-[[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). <i>Journal of Medicinal Chemistry</i> , 2003, 46, 4609-4624.	6.4	129
32	Molecular targets for cell cycle inhibition and cancer therapy. <i>Expert Opinion on Therapeutic Patents</i> , 2003, 13, 329-346.	5.0	6
33	Lysophosphatidic acid acyltransferase-1 β : a novel target for induction of tumour cell apoptosis. <i>Expert Opinion on Therapeutic Targets</i> , 2003, 7, 643-661.	3.4	37
34	Induction of a Senescent-Like Phenotype Does Not Confer the Ability of Bovine Immortal Cells to Support the Development of Nuclear Transfer Embryos ¹ . <i>Biology of Reproduction</i> , 2003, 69, 301-309.	2.7	79
35	Valproate Induces Replication-independent Active DNA Demethylation. <i>Journal of Biological Chemistry</i> , 2003, 278, 27586-27592.	3.4	296
36	The Molecular Perspective: Histone Deacetylase. <i>Oncologist</i> , 2003, 8, 389-391.	3.7	5
37	WNT7a induces E-cadherin in lung cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 10429-10434.	7.1	172
38	Dose-dependent Blockade to Cardiomyocyte Hypertrophy by Histone Deacetylase Inhibitors. <i>Journal of Biological Chemistry</i> , 2003, 278, 28930-28937.	3.4	241

#	ARTICLE	IF	CITATIONS
39	A Homogeneous Nonisotopic Histone Deacetylase Activity Assay. <i>Journal of Biomolecular Screening</i> , 2003, 8, 89-95.	2.6	31
40	Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 4389-4394.	7.1	980
41	Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene. <i>Nucleic Acids Research</i> , 2003, 31, 3123-3133.	14.5	46
42	Deacetylase Activity Is Required for cAMP Activation of a Subset of CREB Target Genes. <i>Journal of Biological Chemistry</i> , 2003, 278, 43014-43019.	3.4	119
43	Involvement of Histone Acetylation in Ovarian Steroid-induced Decidualization of Human Endometrial Stromal Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 16675-16682.	3.4	73
44	Tumor cell-specific cytotoxicity by targeting cell cycle checkpoints. <i>FASEB Journal</i> , 2003, 17, 1-21.	0.5	132
45	Direct Interaction of Ca ²⁺ /Calmodulin Inhibits Histone Deacetylase 5 Repressor Core Binding to Myocyte Enhancer Factor 2. <i>Journal of Biological Chemistry</i> , 2003, 278, 17625-17635.	3.4	39
46	The Epigenome as a Target for Cancer Chemoprevention. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1747-1757.	6.3	109
47	Induction of Apoptosis in BCR/ABL+ Cells By Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways. <i>Cancer Biology and Therapy</i> , 2003, 2, 544-551.	3.4	69
48	An Intact NF-kappaB Pathway is Required for Histone Deacetylase Inhibitor Induced G1 Arrest and Maturation in U937 Human Myeloid Leukemia Cells. <i>Cell Cycle</i> , 2003, 2, 465-470.	2.6	31
49	A Novel Lipid Hydroperoxide-derived Cyclic Covalent Modification to Histone H4. <i>Journal of Biological Chemistry</i> , 2003, 278, 42098-42105.	3.4	63
50	Epigenetic transitions: towards therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2003, 7, 693-699.	3.4	5
51	The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2003, 3, 187-199.	7.0	201
52	Taxonomy, Fermentation, Isolation and Biological Activities.. <i>Journal of Antibiotics</i> , 2003, 56, 72-79.	2.0	75
53	Gene Expression Profiling of Breast Cancers with Emphasis of β -Catenin Regulation. <i>Journal of Korean Medical Science</i> , 2004, 19, 275.	2.5	26
54	Functional Antagonism between NF- κ B and Nuclear Receptors: Implications in Carcinogenesis and Strategies for Optimal Cancer Chemopreventive Interventions. <i>Current Cancer Drug Targets</i> , 2004, 4, 337-344.	1.6	7
55	Enhancement of Antineoplastic Action of 5-Aza-2'-deoxycytidine by Phenylbutyrate on L1210 Leukemic Cells. <i>Leukemia and Lymphoma</i> , 2004, 45, 147-154.	1.3	18
56	Hydroxamic Acids as Pharmacological Agents: An Update. <i>Medicinal Chemistry Reviews Online</i> , 2004, 1, 385-394.	0.1	3

#	ARTICLE	IF	CITATIONS
57	Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15064-15069.	7.1	573
58	Silent Information Regulator 2 β , a Longevity Factor and Class III Histone Deacetylase, Is an Essential Endogenous Apoptosis Inhibitor in Cardiac Myocytes. Circulation Research, 2004, 95, 971-980.	4.5	292
59	Enhanced Radiation-Induced Cell Killing and Prolongation of γ H2AX Foci Expression by the Histone Deacetylase Inhibitor MS-275. Cancer Research, 2004, 64, 316-321.	0.9	215
60	Trichostatin A-induced histone acetylation causes decondensation of interphase chromatin. Journal of Cell Science, 2004, 117, 4277-4287.	2.0	207
61	The Histone Deacetylase Inhibitor MS-275 Interacts Synergistically with Fludarabine to Induce Apoptosis in Human Leukemia Cells. Cancer Research, 2004, 64, 2590-2600.	0.9	141
62	Breast Cancer Metastasis Suppressor 1 (BRMS1) Forms Complexes with Retinoblastoma-binding Protein 1 (RBP1) and the mSin3 Histone Deacetylase Complex and Represses Transcription. Journal of Biological Chemistry, 2004, 279, 1562-1569.	3.4	156
63	Activation of the Growth-Differentiation Factor 11 Gene by the Histone Deacetylase (HDAC) Inhibitor Trichostatin A and Repression by HDAC3. Molecular and Cellular Biology, 2004, 24, 5106-5118.	2.3	90
64	Enhancement of Xenograft Tumor Radiosensitivity by the Histone Deacetylase Inhibitor MS-275 and Correlation with Histone Hyperacetylation. Clinical Cancer Research, 2004, 10, 6066-6071.	7.0	132
65	Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors. Clinical Cancer Research, 2004, 10, 3839-3852.	7.0	371
66	Negative Regulation of Histone Deacetylase 8 Activity by Cyclic AMP-Dependent Protein Kinase A. Molecular and Cellular Biology, 2004, 24, 765-773.	2.3	133
67	Requirement of Histone Deacetylase Activity for Signaling by STAT1. Journal of Biological Chemistry, 2004, 279, 30358-30368.	3.4	163
68	The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584. Cancer Research, 2004, 64, 6626-6634.	0.9	229
69	Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone Resorption. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 369-379.	2.5	33
70	Class I Histone Deacetylase-Selective Novel Synthetic Inhibitors Potently Inhibit Human Tumor Proliferation. Clinical Cancer Research, 2004, 10, 5271-5281.	7.0	139
71	Histone deacetylase (HDAC) inhibitor activation of p21 ^{WAF1} involves changes in promoter-associated proteins, including HDAC1. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1241-1246.	7.1	546
72	Selective Efficacy of Depsipeptide in a Xenograft Model of Epstein-Barr Virus-Positive Lymphoproliferative Disorder. Journal of the National Cancer Institute, 2004, 96, 1447-1457.	6.3	29
73	The Activity of Antiepileptic Drugs as Histone Deacetylase Inhibitors. Epilepsia, 2004, 45, 737-744.	5.1	185
74	Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death and Differentiation, 2004, 11, S193-S206.	11.2	152

#	ARTICLE	IF	CITATIONS
75	Epigenetic modification regulates both expression of tumor-associated genes and cell cycle progressing in human colon cancer cell lines: Colo-320 and SW1116. <i>Cell Research</i> , 2004, 14, 217-226.	12.0	44
76	The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2004, 18, 1207-1214.	7.2	125
77	Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. <i>Leukemia</i> , 2004, 18, 1246-1251.	7.2	120
78	Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. <i>Oncogene</i> , 2004, 23, 5781-5791.	5.9	125
79	Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids. <i>British Journal of Pharmacology</i> , 2004, 141, 874-880.	5.4	210
80	Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases. <i>Structure</i> , 2004, 12, 1325-1334.	3.3	633
81	Combined histone deacetylase and NF- κ B inhibition sensitizes non-small cell lung cancer to cell death. <i>Surgery</i> , 2004, 136, 416-425.	1.9	64
82	Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. <i>Cancer Cell</i> , 2004, 5, 455-463.	16.8	478
83	Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2004, 1693, 167-176.	4.1	67
84	Histone deacetylase inhibitors open new doors in cancer therapy. <i>Biochemical Pharmacology</i> , 2004, 68, 1139-1144.	4.4	141
85	The epigenetics of ovarian cancer drug resistance and resensitization. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 191, 1552-1572.	1.3	156
86	Antiproliferative effect of trichostatin a and hc-toxin in T47D Human breast cancer cells. <i>Archives of Pharmacal Research</i> , 2004, 27, 640-645.	6.3	24
87	Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 2477-2481.	2.2	18
88	Homology modeling, force field design, and free energy simulation studies to optimize the activities of histone deacetylase inhibitors. <i>Journal of Computer-Aided Molecular Design</i> , 2004, 18, 375-388.	2.9	37
89	Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 85-88.	2.3	30
90	Differentiation between peptides containing acetylated or tri-methylated lysines by mass spectrometry: An application for determining lysine 9 acetylation and methylation of histone H3. <i>Proteomics</i> , 2004, 4, 1-10.	2.2	135
91	Effects of the histone deacetylase inhibitor trichostatin A on nuclear texture and c-jun gene expression in drug-sensitive and drug-resistant human H69 lung carcinoma cells. , 2004, 62A, 109-117.		11
92	Acetylation of histones associated with the p21WAF1/CIP1 gene by butyrate is not sufficient for p21WAF1/CIP1 gene transcription in human colorectal adenocarcinoma cells. <i>International Journal of Cancer</i> , 2004, 109, 207-213.	5.1	34

#	ARTICLE	IF	CITATIONS
93	Histone deacetylase inhibitors: Understanding a new wave of anticancer agents. <i>International Journal of Cancer</i> , 2004, 112, 171-178.	5.1	241
94	Regulation of histone deacetylase activities. <i>Journal of Cellular Biochemistry</i> , 2004, 93, 57-67.	2.6	306
95	Prostate specific antigen gene regulation by androgen receptor. <i>Journal of Cellular Biochemistry</i> , 2004, 93, 233-241.	2.6	160
96	Potent histone deacetylase inhibitors: N-hydroxybenzamides with antitumor activities. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 4351-4360.	3.0	16
97	QSAR Studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 707-711.	2.2	42
98	Comparison of peptide mass mapping and electron capture dissociation as assays for histone posttranslational modifications. <i>International Journal of Mass Spectrometry</i> , 2004, 234, 213-225.	1.5	29
99	Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2004, 15, 77-86.	2.8	59
100	Three new cyclostellatamines, which inhibit histone deacetylase, from a marine sponge of the genus <i>Xestospongia</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 2617-2620.	2.2	49
101	Novel treatments in non-small cell lung cancer. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 245-267.	2.2	14
102	3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole-C2 and/or -C4 Substitutions on Biological Activity. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1098-1109.	6.4	61
103	Depsipeptide, a Histone Deacetylase Inhibitor, Shows Promising Clinical Activity in T-Cell Lymphomas. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 15-16.	2.1	0
104	Chromatin targets: reading and writing the cancer cell epigenome. <i>Drug Discovery Today: Disease Models</i> , 2004, 1, 43-48.	1.2	0
105	Zn ²⁺ -Chelating Motif-Tethered Short-Chain Fatty Acids as a Novel Class of Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 467-474.	6.4	99
106	Histone modification enzymes: novel targets for cancer drugs. <i>Expert Opinion on Emerging Drugs</i> , 2004, 9, 135-154.	2.4	70
107	A Wrench-Shaped Synthetic Molecule that Modulates a Transcription Factor Coactivator Interaction. <i>Journal of the American Chemical Society</i> , 2004, 126, 3461-3471.	13.7	58
108	Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 387-400.	2.4	6
109	Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2004, 58, 673-680.	4.3	152
110	Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. <i>Biochemical and Biophysical Research Communications</i> , 2004, 314, 186-191.	2.1	95

#	ARTICLE	IF	CITATIONS
111	Modulation of angiogenesis-related protein synthesis by valproic acid. <i>Biochemical and Biophysical Research Communications</i> , 2004, 316, 693-697.	2.1	67
112	Potent stimulation of gene expression by histone deacetylase inhibitors on transiently transfected DNA. <i>Biochemical and Biophysical Research Communications</i> , 2004, 324, 348-354.	2.1	17
113	Retinoic-acid-induced apoptosis in leukemia cells. <i>Trends in Molecular Medicine</i> , 2004, 10, 508-515.	6.7	45
114	Expression and functional characterization of recombinant human HDAC1 and HDAC3. <i>Life Sciences</i> , 2004, 74, 2693-2705.	4.3	38
115	Molecular Evolution of the Histone Deacetylase Family: Functional Implications of Phylogenetic Analysis. <i>Journal of Molecular Biology</i> , 2004, 338, 17-31.	4.2	1,254
116	3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of Novel Lead Compounds through Structure-Based Drug Design and Docking Studies. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1351-1359.	6.4	65
117	Subtype Selective Substrates for Histone Deacetylases. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 5235-5243.	6.4	121
118	In Vivo Effects of Histone Deacetylase Inhibitor Trichostatin A on Murine Spermatogenesis. <i>Journal of Andrology</i> , 2004, 25, 811-818.	2.0	103
119	Identification and Characterization of Sir2 Inhibitors Through Phenotypic Assays in Yeast. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2004, 7, 661-8.	1.1	8
120	Effect of inhibitors of histone deacetylase on the induction of cell differentiation in murine and human erythroleukemia cell lines. <i>Anti-Cancer Drugs</i> , 2005, 16, 635-643.	1.4	10
122	IFN Unresponsiveness in LNCaP Cells Due to the Lack of <i>JAK1</i> Gene Expression. <i>Cancer Research</i> , 2005, 65, 3447-3453.	0.9	161
123	Modulation of radiation response by histone deacetylase inhibition. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 223-229.	0.8	231
124	Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 1389-1392.	2.2	62
125	Exploring the connection unit in the HDAC inhibitor pharmacophore model: Novel uracil-based hydroxamates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 4656-4661.	2.2	46
126	Advancing chemistry and biology through diversity-oriented synthesis of natural product-like libraries. <i>Current Opinion in Chemical Biology</i> , 2005, 9, 248-258.	6.1	120
127	Histone deacetylase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2005, 40, 1-13.	5.5	342
128	Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2005, 40, 597-606.	5.5	19
129	Nuclear proteins as gene-transfer vectors. <i>Biotechnology and Applied Biochemistry</i> , 2005, 42, 97.	3.1	22

#	ARTICLE	IF	CITATIONS
130	Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 988-994.	2.8	18
131	Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. <i>British Journal of Cancer</i> , 2005, 92, 751-759.	6.4	114
132	Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. <i>Nature Medicine</i> , 2005, 11, 71-76.	30.7	505
133	Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. <i>Nature Medicine</i> , 2005, 11, 77-84.	30.7	567
134	Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. <i>Cell Death and Differentiation</i> , 2005, 12, 10-18.	11.2	99
135	Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. <i>Cell Death and Differentiation</i> , 2005, 12, 395-404.	11.2	301
136	In vivo haematopoietic activity is induced in neurosphere cells by chromatin-modifying agents. <i>EMBO Journal</i> , 2005, 24, 554-566.	7.8	42
137	Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. <i>Leukemia</i> , 2005, 19, 1579-1589.	7.2	65
138	p53 in human embryonal carcinoma: identification of a transferable, transcriptional repression domain in the N-terminal region of p53. <i>Oncogene</i> , 2005, 24, 1481-1490.	5.9	14
139	HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. <i>Oncogene</i> , 2005, 24, 4609-4623.	5.9	178
140	Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis. <i>Pigment Cell & Melanoma Research</i> , 2005, 18, 196-202.	3.6	34
141	Histone deacetylase inhibitors and malignant melanoma. <i>Pigment Cell & Melanoma Research</i> , 2005, 18, 160-166.	3.6	56
142	Histone deacetylase inhibitors and cancer: from cell biology to the clinic. <i>European Journal of Cell Biology</i> , 2005, 84, 109-121.	3.6	111
143	Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. <i>Biochemical Pharmacology</i> , 2005, 69, 1501-1508.	4.4	44
144	Histone Deacetylase Inhibitors: Emerging Anticancer Therapeutic Agents?. <i>Clinical Lung Cancer</i> , 2005, 7, S19-S30.	2.6	23
145	Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. <i>International Journal of Cancer</i> , 2005, 114, 380-386.	5.1	194
146	New method to detect histone acetylation levels by flow cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2005, 66A, 52-61.	1.5	59
147	Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2005, 74, 392-398.	1.4	102

#	ARTICLE	IF	CITATIONS
148	Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. <i>Journal of Nutritional Biochemistry</i> , 2005, 16, 449-466.	4.2	420
149	Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2005, 10, 743-758.	4.9	13
150	The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 385-394.	2.5	70
151	Epigenetic activation of β 4, β 2 and β 6 integrins involved in cell migration in trichostatin A-treated Hep3B cells. <i>Journal of Biomedical Science</i> , 2005, 12, 803-813.	7.0	19
152	Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. <i>Investigational New Drugs</i> , 2005, 23, 99-109.	2.6	50
153	Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. <i>Prostate</i> , 2005, 62, 299-306.	2.3	57
154	High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum. <i>Rapid Communications in Mass Spectrometry</i> , 2005, 19, 1779-1787.	1.5	44
155	New anti-cancer strategies: Epigenetic therapies and biomarkers. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 1897.	3.0	66
156	Synthesis and Biological Evaluation of 2-, 3-, and 4-Acylaminocinnamyl-Nhydroxyamides as Novel Synthetic HDAC Inhibitors. <i>Medicinal Chemistry</i> , 2005, 1, 245-254.	1.5	23
157	Histone Deacetylase Inhibition Down-Regulates Cyclin D1 Transcription by Inhibiting Nuclear Factor- κ B/p65 DNA Binding. <i>Molecular Cancer Research</i> , 2005, 3, 100-109.	3.4	96
158	Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 3697-3702.	7.1	504
159	The role of docosahexaenoic acid in mediating mitochondrial membrane lipid oxidation and apoptosis in colonocytes. <i>Carcinogenesis</i> , 2005, 26, 1914-1921.	2.8	97
160	Epigenetic Modulation of Retinoic Acid Receptor β 2 by the Histone Deacetylase Inhibitor MS-275 in Human Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2005, 11, 3535-3542.	7.0	76
161	Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1222-1230.	4.1	57
162	Targeting epigenetic regulatory mechanisms in cancer chemoprevention. <i>Expert Opinion on Therapeutic Targets</i> , 2005, 9, 315-328.	3.4	7
164	Depsipeptide (FR901228) Enhances the Cytotoxic Activity of TRAIL by Redistributing TRAIL Receptor to Membrane Lipid Rafts. <i>Molecular Therapy</i> , 2005, 11, 542-552.	8.2	81
165	Histone Deacetylase Inhibitors Suppress the Induction of c-Jun and Its Target Genes Including COX-2. <i>Journal of Biological Chemistry</i> , 2005, 280, 32569-32577.	3.4	75
166	Molecular Models of Cancer Development. , 2005, , 3-13.		0

#	ARTICLE	IF	CITATIONS
167	Valproic Acid Induces Apoptosis and Cell Cycle Arrest in Poorly Differentiated Thyroid Cancer Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1383-1389.	3.6	111
168	STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 6948-6953.	7.1	240
169	Histone deacetylase activity is essential for the expression of <i>HoxA9</i> and for endothelial commitment of progenitor cells. <i>Journal of Experimental Medicine</i> , 2005, 201, 1825-1835.	8.5	161
170	Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 4842-4847.	7.1	171
171	Natural Killer Cell-Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate. <i>Cancer Research</i> , 2005, 65, 6321-6329.	0.9	349
172	Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: Involvement of both death receptor and mitochondrial pathways. <i>International Journal of Molecular Medicine</i> , 2005, 16, 1125.	4.0	30
173	Histone Deacetylases as Transcriptional Activators? Role Reversal in Inducible Gene Regulation. <i>Science Signaling</i> , 2005, 2005, re11-re11.	3.6	72
174	Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. <i>Cancer Biology and Therapy</i> , 2005, 4, 1104-1112.	3.4	59
175	Early Clinical Data and Potential Clinical Utility of Novel Histone Deacetylase Inhibitors in Prostate Cancer. <i>Clinical Prostate Cancer</i> , 2005, 4, 83-85.	2.1	2
176	Blockade of Histone Deacetylase Inhibitor-Induced RelA/p65 Acetylation and NF- κ B Activation Potentiates Apoptosis in Leukemia Cells through a Process Mediated by Oxidative Damage, XIAP Downregulation, and c-Jun N-Terminal Kinase 1 Activation. <i>Molecular and Cellular Biology</i> , 2005, 25, 5429-5444.	2.3	237
177	ENHANCED TRANSGENE EXPRESSION IN UROTHELIAL CANCER GENE THERAPY WITH HISTONE DEACETYLASE INHIBITOR. <i>Journal of Urology</i> , 2005, 174, 747-752.	0.4	21
178	Identifying DNA Methylation Biomarkers of Cancer Drug Response. <i>Molecular Diagnosis and Therapy</i> , 2005, 5, 223-232.	3.3	56
179	Structure-Based Optimization of Phenylbutyrate-Derived Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5530-5535.	6.4	96
180	Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review. <i>Molecular Pharmacology</i> , 2005, 68, 917-932.	2.3	223
181	Cancer epigenetics. <i>Human Molecular Genetics</i> , 2005, 14, R65-R76.	2.9	409
182	Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality?. <i>Pharmacogenomics</i> , 2005, 6, 701-711.	1.3	11
183	Alkyl-Substituted Polyaminohydroxamic Acids: A Novel Class of Targeted Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 6350-6365.	6.4	36
184	Development of a PAN-Specific, Affinity-Purified Anti-acetylated Lysine Antibody for Detection, Identification, Isolation, and Intracellular Localization of Acetylated Protein. <i>Journal of Immunoassay and Immunochemistry</i> , 2005, 26, 13-23.	1.1	15

#	ARTICLE	IF	CITATIONS
185	Valproic acid, in combination with all- <i>trans</i> retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced <i>RARβ2</i> in breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 477-486.	4.1	78
186	Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. <i>Journal of Hepatology</i> , 2005, 42, 210-217.	3.7	90
187	Crystal Structure of a Bacterial Class 2 Histone Deacetylase Homologue. <i>Journal of Molecular Biology</i> , 2005, 354, 107-120.	4.2	151
188	Induction of clusterin/apoJ expression by histone deacetylase inhibitors in neural cells. <i>Neurochemistry International</i> , 2005, 47, 528-538.	3.8	35
189	Drug discovery from medicinal plants. <i>Life Sciences</i> , 2005, 78, 431-441.	4.3	1,182
190	Formation of MacroH2A-Containing Senescence-Associated Heterochromatin Foci and Senescence Driven by ASF1a and HIRA. <i>Developmental Cell</i> , 2005, 8, 19-30.	7.0	609
191	Sirtuins (histone deacetylases III) in the cellular response to DNA damage—Facts and hypotheses. <i>DNA Repair</i> , 2005, 4, 1306-1313.	2.8	58
192	Individual histone deacetylases in <i>Drosophila</i> modulate transcription of distinct genes. <i>Genomics</i> , 2005, 86, 606-617.	2.9	67
193	In vitro assays for the determination of histone deacetylase activity. <i>Methods</i> , 2005, 36, 332-337.	3.8	102
194	The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. <i>Trends in Pharmacological Sciences</i> , 2005, 26, 94-103.	8.7	166
195	Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl Hydroxyamides. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3344-3353.	6.4	193
196	Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. <i>Biological Psychiatry</i> , 2005, 57, 500-509.	1.3	243
197	Treatment of Thyroid Cancer with Histone Deacetylase Inhibitors and Peroxisome Proliferator-Activated Receptor β Agonists. <i>Thyroid</i> , 2005, 15, 594-599.	4.5	24
198	DNA Methyltransferase Inhibitors. , 2005, , 187-204.		0
199	Molecular Biology of Human Cancers. , 2005, , .		4
200	Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. <i>Arthritis Research</i> , 2005, 7, R503.	2.0	153
201	A SURVEY OF NOVEL MOLECULAR TARGETS FOR ANTICANCER DRUG DISCOVERY. , 2006, , 1-35.		0
202	High-Content Fluorescence-Based Screening for Epigenetic Modulators. <i>Methods in Enzymology</i> , 2006, 414, 21-36.	1.0	24

#	ARTICLE	IF	CITATIONS
203	From The Cover: The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1587-1592.	7.1	210
204	Histone Deacetylase Inhibitors in Cancer Therapy. Cancer Investigation, 2006, 24, 521-527.	1.3	44
206	Role of Hematopoietic Stem Cell Transplantation for Advanced-Stage Diffuse Large Cell B-Cell Lymphoma-B. Seminars in Hematology, 2006, 43, 240-250.	3.4	15
207	Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases. Journal of Biotechnology, 2006, 124, 258-270.	3.8	80
208	Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Molecular Cancer, 2006, 5, 71.	19.2	87
209	Synthesis and Biological Properties of Novel, Uracil-Containing Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 6046-6056.	6.4	57
210	Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Molecular Cancer Therapeutics, 2006, 5, 3085-3095.	4.1	99
211	Unexpected Deacetylation Mechanism Suggested by a Density Functional Theory QM/MM Study of Histone-Deacetylase-Like Protein. Journal of the American Chemical Society, 2006, 128, 4530-4531.	13.7	98
212	Aromatic Sulfide Inhibitors of Histone Deacetylase Based on Arylsulfinyl-2,4-hexadienoic Acid Hydroxyamides. Journal of Medicinal Chemistry, 2006, 49, 800-805.	6.4	22
213	Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death. Biochemical and Biophysical Research Communications, 2006, 339, 1171-1177.	2.1	44
214	Characterization of the two catalytic domains in histone deacetylase 6. Biochemical and Biophysical Research Communications, 2006, 341, 45-50.	2.1	125
215	The proteomic study of sodium butyrate antiproliferative/cytodifferentiation effects on K562 cells. Blood Cells, Molecules, and Diseases, 2006, 37, 210-217.	1.4	17
216	Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells. Cancer Letters, 2006, 232, 148-160.	7.2	38
217	SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Letters, 2006, 237, 143-154.	7.2	33
218	Histone deacetylase inhibitors: Multifunctional anticancer agents. Cancer Treatment Reviews, 2006, 32, 157-165.	7.7	212
219	The clinical trail of TRAIL. European Journal of Cancer, 2006, 42, 2233-2240.	2.8	162
220	Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1 α . Cancer Research, 2006, 66, 8814-8821.	0.9	292
221	Cell Cycle and Checkpoint Regulation of Histone H3 K56 Acetylation by Hst3 and Hst4. Molecular Cell, 2006, 23, 109-119.	9.7	235

#	ARTICLE	IF	CITATIONS
222	Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 565-566.	1.6	0
224	Induction of Apoptosis by <i>Cordyceps militaris</i> through Activation of Caspase-3 in Leukemia HL-60 Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2006, 29, 670-674.	1.4	51
225	N-methylformamide and 9-hydroxystearic acid: two anti-proliferative and differentiating agents with different modes of action in colon cancer cells. <i>Anti-Cancer Drugs</i> , 2006, 17, 521-526.	1.4	11
227	New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas. <i>JDDG - Journal of the German Society of Dermatology</i> , 2006, 4, 395-405.	0.8	24
228	Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. <i>Nature Reviews Cancer</i> , 2006, 6, 38-51.	28.4	2,049
229	Anticancer activities of histone deacetylase inhibitors. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 769-784.	46.4	2,578
230	Altered sirtuin expression is associated with node-positive breast cancer. <i>British Journal of Cancer</i> , 2006, 95, 1056-1061.	6.4	219
231	Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells. <i>Cell Death and Differentiation</i> , 2006, 13, 446-453.	11.2	81
232	Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. <i>Cancer Gene Therapy</i> , 2006, 13, 628-632.	4.6	30
233	Modulation of cellular radiation responses by histone deacetylase inhibitors. <i>Oncogene</i> , 2006, 25, 3885-3893.	5.9	83
234	Synthesis of rigid trichostatin A analogs as HDAC inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5339-5344.	2.2	19
235	Histone proteins determined in a human colon cancer by high-performance liquid chromatography and mass spectrometry. <i>Journal of Chromatography A</i> , 2006, 1129, 73-81.	3.7	25
236	Adenosine Mimetics as Inhibitors of NAD ⁺ -Dependent Histone Deacetylases, from Kinase to Sirtuin Inhibition. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7307-7316.	6.4	152
237	Pharmacological Inhibition of Histone Deacetylases by Suberoylanilide Hydroxamic Acid Specifically Alters Gene Expression and Reduces Ischemic Injury in the Mouse Brain. <i>Molecular Pharmacology</i> , 2006, 70, 1876-1884.	2.3	231
238	The Wnt-dependent signaling pathways as target in oncology drug discovery. <i>Investigational New Drugs</i> , 2006, 24, 263-280.	2.6	67
240	Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel β -lactam-based histone deacetylase (HDAC) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 4068-4070.	2.2	33
241	A series of novel, potent, and selective histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5948-5952.	2.2	68
242	Histone deacetylase inhibitors as a potential therapeutic agent for human cancer treatment. <i>Targeted Oncology</i> , 2006, 1, 34-41.	3.6	9

#	ARTICLE	IF	CITATIONS
243	Targeted approaches for the management of metastatic prostate cancer. <i>Current Oncology Reports</i> , 2006, 8, 206-212.	4.0	4
244	Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 983-1002.	3.3	180
245	Radiation and New Molecular Agents, Part II: Targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. <i>Seminars in Radiation Oncology</i> , 2006, 16, 59-64.	2.2	52
246	Alteration of Developmental Program in Paramecium by Treatment with Trichostatin A: A Possible Involvement of Histone Modification. <i>Protist</i> , 2006, 157, 303-314.	1.5	4
247	Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. <i>BMC Cancer</i> , 2006, 6, 214.	2.6	40
248	Inhibition of histone deacetylase as a new mechanism of teratogenesis. <i>Birth Defects Research Part C: Embryo Today Reviews</i> , 2006, 78, 345-353.	3.6	71
249	Aroyl-Pyrrolyl Hydroxyamides: Influence of Pyrrole C4-Phenylacetyl Substitution on Histone Deacetylase Inhibition. <i>ChemMedChem</i> , 2006, 1, 225-237.	3.2	20
250	Molecularly targeted therapy for melanoma. <i>Cancer</i> , 2006, 107, 2317-2327.	4.1	50
251	HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. <i>Hepatology</i> , 2006, 43, 425-434.	7.3	111
252	Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. <i>International Journal of Cancer</i> , 2006, 118, 1041-1050.	5.1	41
253	SAHA-sensitized prostate cancer cells to TNF α -related apoptosis-inducing ligand (TRAIL): Mechanisms leading to synergistic apoptosis. <i>International Journal of Cancer</i> , 2006, 119, 221-228.	5.1	53
254	The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. <i>International Journal of Cancer</i> , 2006, 119, 944-954.	5.1	68
255	Synthesis of [phenyl-U-14C]aryl and [8-14C]carboxy labeled tracers of vorinostat. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 437-443.	1.0	4
256	Radiosynthesis of 6-([18F]fluoroacetamido)-1-hexanoicanilide ([18F]FAHA) for PET imaging of histone deacetylase (HDAC). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 997-1006.	1.0	20
257	Histone Deacetylase Inhibitors for Cancer Therapy. <i>Epigenetics</i> , 2006, 1, 15-24.	2.7	61
258	Histone Deacetylases as Targets for Dietary Cancer Preventive Agents: Lessons Learned with Butyrate, Diallyl Disulfide, and Sulforaphane. <i>Current Drug Targets</i> , 2006, 7, 443-452.	2.1	158
259	Clinical Potential of Histone Deacetylase Inhibitors as Stand Alone Therapeutics and in Combination with other Chemotherapeutics or Radiotherapy for Cancer. <i>Epigenetics</i> , 2006, 1, 121-126.	2.7	35
260	The Epigenetic Modifier, Valproic Acid, Enhances Radiation Sensitivity. <i>Epigenetics</i> , 2006, 1, 131-137.	2.7	42

#	ARTICLE	IF	CITATIONS
261	DNA Methylation and Histone Modifications in Patients With Cancer: Potential Prognostic and Therapeutic Targets. , 2007, 361, 25-62.		63
262	CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1693-1701.	4.1	27
263	Acetylation of p53 at Lysine 373/382 by the Histone Deacetylase Inhibitor Depsipeptide Induces Expression of p21 Waf1/Cip1. <i>Molecular and Cellular Biology</i> , 2006, 26, 2782-2790.	2.3	265
264	Down-regulation of Histone Deacetylases Stimulates Adipocyte Differentiation. <i>Journal of Biological Chemistry</i> , 2006, 281, 6608-6615.	3.4	160
265	A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. <i>Genes and Development</i> , 2006, 20, 2566-2579.	5.9	154
266	Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. <i>Endocrine-Related Cancer</i> , 2006, 13, 1237-1250.	3.1	62
267	Active Transcription of the Human FASL/CD95L/TNFSF6 Promoter Region in T Lymphocytes Involves Chromatin Remodeling. <i>Journal of Biological Chemistry</i> , 2006, 281, 14719-14728.	3.4	16
268	Histone Deacetylation as a Target for Radiosensitization. <i>Current Topics in Developmental Biology</i> , 2006, 73, 173-204.	2.2	48
269	Quantitative Proteomic Analysis of Post-translational Modifications of Human Histones. <i>Molecular and Cellular Proteomics</i> , 2006, 5, 1314-1325.	3.8	168
270	Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589. <i>Clinical Cancer Research</i> , 2006, 12, 634-642.	7.0	264
271	The epigenetic basis for the aberrant expression of kallikreins in human cancers. <i>Biological Chemistry</i> , 2006, 387, 795-9.	2.5	30
272	Mechanisms of Cell Death Induced by Histone Deacetylase Inhibitors in Androgen Receptor-Positive Prostate Cancer Cells. <i>Molecular Cancer Research</i> , 2006, 4, 113-123.	3.4	67
273	Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 3997-4003.	7.0	235
274	Antitumor Effects of a Novel Phenylbutyrate-Based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 5199-5206.	7.0	93
275	Suppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy. <i>Circulation</i> , 2006, 113, 2579-2588.	1.6	328
276	Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer. <i>Journal of Biological Chemistry</i> , 2006, 281, 13548-13558.	3.4	486
277	G1/S Arrest Induced by Histone Deacetylase Inhibitor Sodium Butyrate in E1A + Ras-transformed Cells Is Mediated through Down-regulation of E2F Activity and Stabilization of β -Catenin. <i>Journal of Biological Chemistry</i> , 2006, 281, 21040-21051.	3.4	61
278	Transcriptional Silencing of the Death Gene BNIP3 by Cooperative Action of NF- κ B and Histone Deacetylase 1 in Ventricular Myocytes. <i>Circulation Research</i> , 2006, 99, 1347-1354.	4.5	67

#	ARTICLE	IF	CITATIONS
279	Genetics and Epigenetics in Cancer Biology. , 2006, , 25-56.		1
280	CpG Island Methylation and Histone Modifications: Biology and Clinical Significance. , 2006, , 115-126.		21
281	Assays for pharmacodynamic analysis of histone deacetylase inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2006, 2, 213-230.	3.3	15
282	The cAMP Pathway in Combination with BMP2 Regulates Phox2a Transcription via cAMP Response Element Binding Sites. Journal of Biological Chemistry, 2006, 281, 2969-2981.	3.4	17
283	Locus-Wide Chromatin Remodeling and Enhanced Androgen Receptor-Mediated Transcription in Recurrent Prostate Tumor Cells. Molecular and Cellular Biology, 2006, 26, 7331-7341.	2.3	62
284	Histone Deacetylase (HDAC) Inhibitor LBH589 Increases Duration of γ -H2AX Foci and Confines HDAC4 to the Cytoplasm in Irradiated Non-Small Cell Lung Cancer. Cancer Research, 2006, 66, 11298-11304.	0.9	160
285	Histone Deacetylase Inhibitors Modulate the Sensitivity of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Resistant Bladder Tumor Cells. Cancer Research, 2006, 66, 499-507.	0.9	80
286	Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Report. Journal of Clinical Oncology, 2006, 24, 3678-3685.	1.6	81
287	Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis. Cancer Research, 2006, 66, 6785-6792.	0.9	124
288	Chromatin Acetylation Status in the Manifestation of Neurodegenerative Diseases. Sub-Cellular Biochemistry, 2007, , 269-300.	2.4	7
289	Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18682-18687.	7.1	96
290	Histone Deacetylase Inhibitor Trichostatin A Sustains Sodium Pervanadate-induced NF- κ B Activation by Delaying β -tubulin mRNA Resynthesis. Journal of Biological Chemistry, 2007, 282, 15383-15393.	3.4	20
291	Histone Deacetylase Inhibitors Suppress TF- κ B-dependent Agonist-driven Tissue Factor Expression in Endothelial Cells and Monocytes. Journal of Biological Chemistry, 2007, 282, 28408-28418.	3.4	64
292	Histone deacetylase inhibitors. Expert Opinion on Therapeutic Patents, 2007, 17, 745-765.	5.0	10
293	Relationship between Embryonic Histone Hyperacetylation and Axial Skeletal Defects in Mouse Exposed to the Three HDAC Inhibitors Apicidin, MS-275, and Sodium Butyrate. Toxicological Sciences, 2007, 98, 582-588.	3.1	19
294	Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells. Current Pharmaceutical Biotechnology, 2007, 8, 388-400.	1.6	138
295	Epigenetic Lesions in Malignant Melanoma. Current Pharmaceutical Biotechnology, 2007, 8, 382-387.	1.6	30
296	Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. Molecular Cancer Therapeutics, 2007, 6, 1425-1432.	4.1	76

#	ARTICLE	IF	CITATIONS
297	Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury. <i>Cardiovascular Research</i> , 2007, 76, 473-481.	3.8	131
298	Role for Histone Deacetylase 1 in Human Tumor Cell Proliferation. <i>Molecular and Cellular Biology</i> , 2007, 27, 4784-4795.	2.3	222
299	Inhibition of Histone Deacetylation: A Strategy for Tumor Radiosensitization. <i>Journal of Clinical Oncology</i> , 2007, 25, 4051-4056.	1.6	160
300	Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation. <i>Clinical Cancer Research</i> , 2007, 13, 4280-4290.	7.0	63
301	Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval. <i>Journal of Clinical Oncology</i> , 2007, 25, 3362-3371.	1.6	198
302	Characterization of a Gene Cluster Responsible for the Biosynthesis of Anticancer Agent FK228 in <i>Chromobacterium violaceum</i> No. 968. <i>Applied and Environmental Microbiology</i> , 2007, 73, 3460-3469.	3.1	57
303	Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 70-81.	4.1	74
304	SOX6 Suppresses Cyclin D1 Promoter Activity by Interacting with β -Catenin and Histone Deacetylase 1, and Its Down-regulation Induces Pancreatic β -Cell Proliferation. <i>Journal of Biological Chemistry</i> , 2007, 282, 19052-19061.	3.4	122
305	A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17777-17782.	7.1	78
306	Inhibition of histone deacetylase activity induces developmental plasticity in oligodendrocyte precursor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 14982-14987.	7.1	115
307	Histone Deacetylase Inhibitors Induce Premature Sister Chromatid Separation and Override the Mitotic Spindle Assembly Checkpoint. <i>Cancer Research</i> , 2007, 67, 6360-6367.	0.9	48
308	Synergistic <i>in vivo</i> Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 4538-4546.	7.0	82
309	1. Molecular Target Drug Discovery. <i>Internal Medicine</i> , 2007, 46, 87-90.	0.7	3
310	An active site tyrosine residue is essential for amidohydrolase but not for esterase activity of a class 2 histone deacetylase-like bacterial enzyme. <i>Biochemical Journal</i> , 2007, 401, 659-665.	3.7	20
311	Polyamine-based analogues as biochemical probes and potential therapeutics. <i>Biochemical Society Transactions</i> , 2007, 35, 356-363.	3.4	24
312	Histone deacetylase inhibitors suppress IFN α -induced up-regulation of promyelocytic leukemia protein. <i>Blood</i> , 2007, 109, 1373-1380.	1.4	40
313	Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). <i>Blood</i> , 2007, 109, 31-39.	1.4	1,056
314	A Simple and Sensitive High-Performance Liquid Chromatographic Method for Quantification of PXD101, a Histone Deacetylase Inhibitor in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 231-235.	2.0	3

#	ARTICLE	IF	CITATIONS
315	Histone deacetylase inhibitors for epigenetic therapy of cancer. <i>Anti-Cancer Drugs</i> , 2007, 18, 363-370.	1.4	47
316	Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation. <i>Anti-Cancer Drugs</i> , 2007, 18, 793-800.	1.4	37
317	Aberrant epigenetics in rheumatoid arthritis and osteoarthritis. <i>Future Rheumatology</i> , 2007, 2, 257-260.	0.2	1
318	HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit. <i>Topics in Medicinal Chemistry</i> , 2007, , 293-331.	0.8	9
319	Retinoblastoma epidemiology: Does the evidence matter?. <i>European Journal of Cancer</i> , 2007, 43, 1596-1603.	2.8	27
320	A novel embryotoxic estimation method of VPA using ES cells differentiation system. <i>Biochemical and Biophysical Research Communications</i> , 2007, 352, 164-169.	2.1	23
321	FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. <i>Biochemical and Biophysical Research Communications</i> , 2007, 356, 998-1003.	2.1	56
322	MS-275, a potent orally available inhibitor of histone deacetylasesâ€”The development of an anticancer agent. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1388-1405.	2.8	134
323	Novel pyrrole-containing histone deacetylase inhibitors endowed with cytodifferentiation activity. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1510-1522.	2.8	13
324	Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells. <i>International Immunopharmacology</i> , 2007, 7, 1422-1432.	3.8	21
325	Is SIRT6 a new biomarker for oxidative stress and longevity assurance gene?. <i>Medical Hypotheses</i> , 2007, 69, 231.	1.5	5
326	The aryl hydrocarbon receptor agonist 3,3â€²,4,4â€²,5-pentachlorobiphenyl induces distinct patterns of gene expression between hepatoma and glioma cells: Chromatin remodeling as a mechanism for selective effects. <i>NeuroToxicology</i> , 2007, 28, 594-612.	3.0	17
327	Synthesis of triglycerides of phenylalkanoic acids by lipase-catalyzed esterification in a solvent-free system. <i>Journal of Biotechnology</i> , 2007, 127, 694-702.	3.8	11
328	Target-Based Approach to Inhibitors of Histone Arginine Methyltransferases. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 2319-2325.	6.4	137
329	In vivo transcriptional targeting into the retinal vasculature using recombinant baculovirus carrying the human flt-1 promoter. <i>Virology Journal</i> , 2007, 4, 88.	3.4	20
330	BCoR-L1 variation and breast cancer. <i>Breast Cancer Research</i> , 2007, 9, R54.	5.0	10
331	Mass spectrometry-based strategies for characterization of histones and their post-translational modifications. <i>Expert Review of Proteomics</i> , 2007, 4, 211-225.	3.0	38
332	Molecular Insights into Azumamide E Histone Deacetylases Inhibitory Activity. <i>Journal of the American Chemical Society</i> , 2007, 129, 3007-3012.	13.7	89

#	ARTICLE	IF	CITATIONS
333	Cutaneous T-Cell Lymphoma: Overview and Nursing Perspectives. <i>Nursing Clinics of North America</i> , 2007, 42, 421-455.	1.5	7
334	A Histone Deacetylase Inhibitor Enhances Adenoviral Infection of Renal Cancer Cells. <i>Journal of Urology</i> , 2007, 177, 1148-1156.	0.4	15
335	The role of histone deacetylases (HDACs) in human cancer. <i>Molecular Oncology</i> , 2007, 1, 19-25.	4.6	796
336	The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. <i>Molecular Cancer</i> , 2007, 6, 24.	19.2	663
337	Enhancing the anti-angiogenic action of histone deacetylase inhibitors. <i>Molecular Cancer</i> , 2007, 6, 68.	19.2	24
338	In Vivo Application of Histone Deacetylase Inhibitor Trichostatinâ€ Impairs Murine Male Meiosis. <i>Journal of Andrology</i> , 2008, 29, 172-185.	2.0	38
339	Histone Deacetylase Inhibitors Enhance Lexatumumab-Induced Apoptosis via a p21Cip1-Dependent Decrease in Survivin Levels. <i>Cancer Research</i> , 2007, 67, 6987-6994.	0.9	61
340	From the bench to the bedside: emerging new treatments in multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 797-816.	1.7	63
341	The therapeutic uses of chromatin-modifying agents. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 835-851.	3.4	54
342	Development of histone deacetylase inhibitors for cancer treatment. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 583-598.	2.4	141
343	Chapter 32 To Market, To Market â€ 2006. <i>Annual Reports in Medicinal Chemistry</i> , 2007, 42, 505-554.	0.9	12
344	Beyond Field Effect: Analysis of Shrunken Centroids in Normal Esophageal Epithelia Detects Concomitant Esophageal Adenocarcinoma. <i>Bioinformatics and Biology Insights</i> , 2007, 1, BBI.S311.	2.0	6
345	Molecular Targets and Early Response Biomarkers for the Prediction of Developmental Toxicity<i>In Vitro</i>. <i>ATLA Alternatives To Laboratory Animals</i> , 2007, 35, 335-342.	1.0	8
346	Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. <i>International Journal of Cancer</i> , 2007, 120, 1787-1794.	5.1	96
347	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. <i>International Journal of Cancer</i> , 2007, 121, 656-665.	5.1	173
348	Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. <i>Hepatology</i> , 2007, 46, 1119-1130.	7.3	84
349	The Design of Inhibitors for Medicinally Relevant Metalloproteins. <i>ChemMedChem</i> , 2007, 2, 152-171.	3.2	125
350	Synthesis and Biological Validation of Novel Synthetic Histone/Protein Methyltransferase Inhibitors. <i>ChemMedChem</i> , 2007, 2, 987-991.	3.2	52

#	ARTICLE	IF	CITATIONS
351	Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 136-141.	2.2	17
352	Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in <i>Candida albicans</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 1221-1225.	2.2	84
353	ω-Alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: A study of chain-length and stereochemical dependence. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6261-6265.	2.2	29
354	Modification of cap group in lactam-based histone deacetylase (HDAC) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6234-6238.	2.2	27
355	Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 6142-6146.	2.2	15
356	Trithiocarbonates: Exploration of a new head group for HDAC inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4746-4752.	2.2	32
357	Complex structure of a bacterial class 2 histone deacetylase homologue with a trifluoromethylketone inhibitor. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2007, 63, 270-273.	0.7	30
358	Simultaneous metabolic labeling of cells with multiple amino acids: Localization and dynamics of histone acetylation and methylation. <i>Proteomics - Clinical Applications</i> , 2007, 1, 130-142.	1.6	4
359	Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. <i>Prostate</i> , 2007, 67, 1182-1193.	2.3	65
360	Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. <i>Oncogene</i> , 2007, 26, 91-101.	5.9	68
361	Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. <i>Oncogene</i> , 2007, 26, 4969-4978.	5.9	102
362	HDAC3: taking the SMRT-N-CoR/rect road to repression. <i>Oncogene</i> , 2007, 26, 5439-5449.	5.9	188
363	Deacetylase inhibition promotes the generation and function of regulatory T cells. <i>Nature Medicine</i> , 2007, 13, 1299-1307.	30.7	835
364	Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?. <i>Leukemia</i> , 2007, 21, 61-65.	7.2	96
365	R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. <i>British Journal of Cancer</i> , 2007, 97, 1344-1353.	6.4	86
366	Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. <i>British Journal of Pharmacology</i> , 2007, 150, 862-872.	5.4	247
367	Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo. <i>International Journal of Urology</i> , 2007, 14, 838-845.	1.0	23
368	Dual targeting of epigenetic therapy in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2007, 1775, 76-91.	7.4	85

#	ARTICLE	IF	CITATIONS
369	Mitochondria-mediated and p53-associated apoptosis induced in human cancer cells by a novel selenophene derivative, D-501036. <i>Biochemical Pharmacology</i> , 2007, 73, 610-619.	4.4	69
370	Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression. <i>Biochemical Pharmacology</i> , 2007, 74, 465-476.	4.4	30
371	Depsipeptide a histone deacetylase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). <i>Chemico-Biological Interactions</i> , 2007, 165, 220-229.	4.0	38
372	Isoform-specific up-regulation of plasma membrane Ca ²⁺ ATPase expression during colon and gastric cancer cell differentiation. <i>Cell Calcium</i> , 2007, 42, 590-605.	2.4	63
373	Mechanisms of HDAC inhibitor-induced thrombocytopenia. <i>European Journal of Pharmacology</i> , 2007, 571, 88-96.	3.5	45
374	HDAC inhibition amplifies gap junction communication in neural progenitors: Potential for cell-mediated enzyme prodrug therapy. <i>Experimental Cell Research</i> , 2007, 313, 2958-2967.	2.6	25
375	In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 104, 596-601.	1.4	56
376	Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells. <i>Gynecologic Oncology</i> , 2007, 105, 493-500.	1.4	29
377	Boric acid inhibits embryonic histone deacetylases: A suggested mechanism to explain boric acid-related teratogenicity. <i>Toxicology and Applied Pharmacology</i> , 2007, 220, 178-185.	2.8	53
378	Clinical Significance of Histone Deacetylase Inhibitors in Cancer. , 2007, , 335-361.		0
379	Syntheses of Amamistatin Fragments and Determination of Their HDAC and Antitumor Activity. <i>Organic Letters</i> , 2007, 9, 1683-1685.	4.6	44
380	Distribution of histone deacetylases 11 in the rat brain. <i>Journal of Molecular Neuroscience</i> , 2007, 31, 47-58.	2.3	311
381	Epigenetic mechanisms in the context of complex diseases. <i>Cellular and Molecular Life Sciences</i> , 2007, 64, 1531-1538.	5.4	157
382	Histone deacetylases: Focus on the nervous system. <i>Cellular and Molecular Life Sciences</i> , 2007, 64, 2258-2269.	5.4	83
383	Roles of histone acetylation modification in basal and inducible expression of hsp26 gene in <i>D. melanogaster</i> . <i>Molecular and Cellular Biochemistry</i> , 2007, 306, 1-8.	3.1	7
384	Valproic acid induces p21 and topoisomerase-II (\pm/\hat{I}^2) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. <i>Journal of Neuro-Oncology</i> , 2007, 85, 159-170.	2.9	100
385	Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2007, 12, 561-571.	4.9	45
386	Inactivation of NF- κ B by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 53-62.	2.5	41

#	ARTICLE	IF	CITATIONS
387	Histone deacetylases: target enzymes for cancer therapy. <i>Clinical and Experimental Metastasis</i> , 2008, 25, 183-189.	3.3	145
388	Analysis of human histone H4 by capillary electrophoresis in a pullulan-coated capillary, LC-ESI-MS and MALDI-TOF-MS. <i>Analytical and Bioanalytical Chemistry</i> , 2008, 390, 1881-1888.	3.7	12
389	Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. <i>Journal of Molecular Medicine</i> , 2008, 86, 117-128.	3.9	45
390	Sodium arsenite modulates histone acetylation, histone deacetylase activity and HMGN protein dynamics in human cells. <i>Chromosoma</i> , 2008, 117, 147-157.	2.2	90
391	Identification of a subunit of NADH-dehydrogenase as a p49/STRAP-binding protein. <i>BMC Cell Biology</i> , 2008, 9, 8.	3.0	17
392	Thio-barbiturates as Sirtuin Inhibitors: Virtual Screening, Free Energy Calculations, and Biological Testing. <i>ChemMedChem</i> , 2008, 3, 1965-1976.	3.2	59
393	Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. <i>International Journal of Cancer</i> , 2008, 123, 2774-2781.	5.1	60
394	Valproic acid: A viable alternative to sodium butyrate for enhancing protein expression in mammalian cell cultures. <i>Biotechnology and Bioengineering</i> , 2008, 101, 182-189.	3.3	145
395	Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. <i>Journal of Molecular Graphics and Modelling</i> , 2008, 26, 1160-1168.	2.4	60
396	Class II-selective histone deacetylase inhibitors. Part 2: Alignment-independent GRIND 3-D QSAR, homology and docking studies. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 621-632.	5.5	39
397	Synthesis and biological evaluation of histone deacetylase inhibitors that are based on FR235222: A cyclic tetrapeptide scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2549-2554.	2.2	21
398	Optimization of a series of potent and selective ketone histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5528-5532.	2.2	12
399	In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors. <i>International Journal of Pharmaceutics</i> , 2008, 361, 19-25.	5.2	72
400	Cancer Epigenetics: Modifications, Screening, and Therapy. <i>Annual Review of Medicine</i> , 2008, 59, 267-280.	12.2	241
401	MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity <i>in vitro</i> and <i>in vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2008, 7, 759-768.	4.1	303
402	Histone Deacetylase Inhibitors: Mechanisms and Clinical Significance in Cancer: HDAC Inhibitor-Induced Apoptosis. <i>Advances in Experimental Medicine and Biology</i> , 2008, 615, 261-298.	1.6	141
403	Pluripotency Associated Genes Are Reactivated by Chromatin-Modifying Agents in Neurosphere Cells. <i>Stem Cells</i> , 2008, 26, 920-926.	3.2	85
404	Monitoring the effect of belinostat in solid tumors by H4 acetylation. <i>Apmis</i> , 2008, 116, 382-392.	2.0	16

#	ARTICLE	IF	CITATIONS
405	Epigenetic plasticity of chromatin in embryonic and hematopoietic stem/progenitor cells: therapeutic potential of cell reprogramming. <i>Leukemia</i> , 2008, 22, 1503-1518.	7.2	55
406	Targeted therapy in leukemia. <i>Modern Pathology</i> , 2008, 21, S2-S7.	5.5	12
407	The histone deacetylase inhibitor trichostatin A induces GADD45 ¹³ expression via Oct and NF- κ B binding sites. <i>Oncogene</i> , 2008, 27, 1263-1272.	5.9	30
408	Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. <i>Histopathology</i> , 2008, 53, 267-277.	2.9	109
409	Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. <i>Cancer Science</i> , 2008, 99, 376-384.	3.9	79
410	HDAC2 deficiency sensitizes colon cancer cells to TNF α -induced apoptosis through inhibition of NF- κ B activity. <i>Experimental Cell Research</i> , 2008, 314, 1507-1518.	2.6	29
411	Epigenetic silencing of the WNT antagonist DICKKOPF-1 in cervical cancer cell lines. <i>Gynecologic Oncology</i> , 2008, 109, 270-274.	1.4	54
412	BM88/Cend1 is involved in histone deacetylase inhibition-mediated growth arrest and differentiation of neuroblastoma cells. <i>FEBS Letters</i> , 2008, 582, 741-748.	2.8	17
413	HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2008, 1783, 2030-2038.	4.1	48
414	Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A. <i>Biochemical Pharmacology</i> , 2008, 76, 463-475.	4.4	67
415	Butyrate inhibits functional differentiation of human monocyte-derived dendritic cells. <i>Cellular Immunology</i> , 2008, 253, 54-58.	3.0	72
416	Chromatin, cancer and drug therapies. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2008, 647, 44-51.	1.0	68
417	Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. <i>Molecular Cancer</i> , 2008, 7, 55.	19.2	54
418	Cutaneous T-cell lymphoma and emerging therapies. <i>Drug Discovery Today Disease Mechanisms</i> , 2008, 5, e69-e79.	0.8	0
419	Decreased Acetylation of Histone H3 in Renal Cell Carcinoma: A Potential Target of Histone Deacetylase Inhibitors. <i>Journal of Urology</i> , 2008, 180, 1131-1136.	0.4	37
420	Other Approaches to Targeted Therapy. , 2008, , 307-349.		0
421	The efficacy of combination therapy using adeno-associated virus ² and trichostatin A in vitro and in a murine model of neuroblastoma. <i>Journal of Pediatric Surgery</i> , 2008, 43, 177-183.	1.6	15
422	Effects of Histone Deacetylase Inhibitor SAHA on Effector and FOXP3+Regulatory T Cells in Rhesus Macaques. <i>Transplantation Proceedings</i> , 2008, 40, 459-461.	0.6	33

#	ARTICLE	IF	CITATIONS
423	Autophagy induced by suberoylanilide hydroxamic acid in HeLa S3 cells involves inhibition of protein kinase B and up-regulation of Beclin 1. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 272-283.	2.8	39
424	Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. <i>Biomedicine and Pharmacotherapy</i> , 2008, 62, 85-93.	5.6	35
425	Multi-targeted prevention of cancer by sulforaphane. <i>Cancer Letters</i> , 2008, 269, 291-304.	7.2	457
426	Inhibition of tumor-stromal interaction through HGF/Met signaling by valproic acid. <i>Biochemical and Biophysical Research Communications</i> , 2008, 366, 110-116.	2.1	21
427	Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. <i>Biochemical and Biophysical Research Communications</i> , 2008, 368, 318-322.	2.1	89
428	Histone deacetylase inhibitors from microorganisms: the Astellas experience. , 2008, 66, 335-359.		13
429	Histone deacetylase inhibitors suppress interleukin-1 β -induced nitric oxide and prostaglandin E2 production in human chondrocytes. <i>Osteoarthritis and Cartilage</i> , 2008, 16, 1267-1274.	1.3	151
430	Cutaneous T-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 979-996.	2.2	31
431	Structure-Activity Studies on Splitomicin Derivatives as Sirtuin Inhibitors and Computational Prediction of Binding Mode. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1203-1213.	6.4	159
432	5-Aza-2'-deoxycytidine Restores Proapoptotic Function of p53 in Cancer Cells Resistant to p53-induced Apoptosis. <i>Cancer Investigation</i> , 2008, 26, 680-688.	1.3	11
433	Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. <i>Biochemical Journal</i> , 2008, 409, 581-589.	3.7	667
434	Efficient Solid-Phase Synthesis of FK228 Analogues as Potent Antitumoral Agents. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6639-6641.	6.4	31
435	Polyaminohydroxamic Acids and Polyaminobenzamides as Isoform Selective Histone Deacetylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2447-2456.	6.4	32
436	Total Synthesis and Biological Mode of Action of Largazole: A Potent Class I Histone Deacetylase Inhibitor. <i>Journal of the American Chemical Society</i> , 2008, 130, 11219-11222.	13.7	165
437	Syntheses and Biological Activity of Amamistatin B and Analogs. <i>Journal of Organic Chemistry</i> , 2008, 73, 1018-1024.	3.2	43
438	Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 4500-4510.	7.0	286
439	Histone Deacetylase Inhibition and Blockade of the Glycolytic Pathway Synergistically Induce Glioblastoma Cell Death. <i>Clinical Cancer Research</i> , 2008, 14, 3132-3140.	7.0	54
441	Sp1-Mediated TRAIL Induction in Chemosensitization. <i>Cancer Research</i> , 2008, 68, 6718-6726.	0.9	46

#	ARTICLE	IF	CITATIONS
442	Presentation of Telomerase Reverse Transcriptase, a Self-Tumor Antigen, is Down-regulated by Histone Deacetylase Inhibition. <i>Cancer Research</i> , 2008, 68, 8085-8093.	0.9	27
443	HDACs and HDAC inhibitors in colon cancer. <i>Epigenetics</i> , 2008, 3, 28-37.	2.7	192
444	Epigenetic changes in gliomas. <i>Cancer Biology and Therapy</i> , 2008, 7, 1326-1334.	3.4	29
445	HDAC1 Promotes Liver Proliferation in Young Mice via Interactions with C/EBP β . <i>Journal of Biological Chemistry</i> , 2008, 283, 26179-26187.	3.4	55
446	Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model. <i>Experimental and Molecular Medicine</i> , 2008, 40, 574.	7.7	54
447	Histone Modifications at the <i>ABCG2</i> Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells. <i>Molecular Cancer Research</i> , 2008, 6, 151-164.	3.4	119
448	Drosophila Histone Deacetylase-3 Controls Imaginal Disc Size through Suppression of Apoptosis. <i>PLoS Genetics</i> , 2008, 4, e1000009.	3.5	25
449	The Inhibition of Embryonic Histone Deacetylases as the Possible Mechanism Accounting for Axial Skeletal Malformations Induced by Sodium Salicylate. <i>Toxicological Sciences</i> , 2008, 104, 397-404.	3.1	20
450	Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 779-787.	4.1	22
451	Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay. <i>Clinical Cancer Research</i> , 2008, 14, 3441-3449.	7.0	88
452	Mining the Epigenome for Methylated Genes in Lung Cancer. <i>Proceedings of the American Thoracic Society</i> , 2008, 5, 806-810.	3.5	33
453	Targeting Epigenetic Mechanisms: Potential of Natural Products in Cancer Chemoprevention. <i>Planta Medica</i> , 2008, 74, 1593-1601.	1.3	55
454	Targeting Cancer and Neuropathy with Histone Deacetylase Inhibitors: Two Birds with One Stone?. <i>Current Cancer Drug Targets</i> , 2008, 8, 266-274.	1.6	9
455	Trichostatin A and Oncolytic HSV Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects. <i>Molecular Therapy</i> , 2008, 16, 1041-1047.	8.2	74
456	Novel Method for Selecting Immunosuppressive Histone Deacetylase (HDAC) Inhibitors with Minimal Thrombocytopenia. <i>Biological and Pharmaceutical Bulletin</i> , 2008, 31, 305-308.	1.4	6
457	Effect of a New Immunosuppressant Histone Deacetylase (HDAC) Inhibitor FR276457 in a Rat Cardiac Transplant Model. <i>Biological and Pharmaceutical Bulletin</i> , 2008, 31, 1723-1726.	1.4	23
458	Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. <i>Blood</i> , 2008, 112, 981-989.	1.4	229
459	Alternative Modes of Binding of Recombinant Human Histone Deacetylase 8 to Colloidal Gold Nanoparticles. <i>Journal of Biomedical Nanotechnology</i> , 2008, 4, 463-468.	1.1	18

#	ARTICLE	IF	CITATIONS
460	Histone Deacetylase Inhibitors as Novel Anticancer Therapeutics. <i>Current Oncology</i> , 2008, 15, 237-243.	2.2	84
461	Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 2562-73.	8.2	243
462	FE65 Binds Teashirt, Inhibiting Expression of the Primate-Specific Caspase-4. <i>PLoS ONE</i> , 2009, 4, e5071.	2.5	33
463	Anti-Leukemia Activity of MS-275 Histone Deacetylase Inhibitor Implicates 4-1BBL/4-1BB Immunomodulatory Functions. <i>PLoS ONE</i> , 2009, 4, e7085.	2.5	18
464	Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown <i>in vitro</i> and as intracranial xenografts. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1589-1595.	4.1	71
465	High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model. <i>Clinical Cancer Research</i> , 2009, 15, 4066-4076.	7.0	53
466	Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells. <i>Clinical Cancer Research</i> , 2009, 15, 840-850.	7.0	100
467	p53 Acetylation Is Crucial for Its Transcription-independent Proapoptotic Functions. <i>Journal of Biological Chemistry</i> , 2009, 284, 11171-11183.	3.4	111
468	Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 3088-3097.	4.1	31
469	Valproate, in Combination with Pemetrexed and Cisplatin, Provides Additional Efficacy to the Treatment of Malignant Mesothelioma. <i>Clinical Cancer Research</i> , 2009, 15, 2818-2828.	7.0	86
470	The Changing Face of HDAC Inhibitor Depsipeptide. <i>Current Cancer Drug Targets</i> , 2009, 9, 91-100.	1.6	22
471	Targeted therapy in acute myeloid leukaemia: current status and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 433-455.	4.1	34
472	Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2844-2851.	4.1	23
473	JNJ-26481585, a Novel Second-Generation Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity. <i>Clinical Cancer Research</i> , 2009, 15, 6841-6851.	7.0	190
474	Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells <i>in vitro</i> and <i>in vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2009, 8, 802-808.	4.1	36
475	Rational Combinations Using HDAC Inhibitors. <i>Clinical Cancer Research</i> , 2009, 15, 3970-3977.	7.0	207
476	Inhibitors of Deacetylases Suppress Oncogenic KIT Signaling, Acetylate HSP90, and Induce Apoptosis in Gastrointestinal Stromal Tumors. <i>Cancer Research</i> , 2009, 69, 6941-6950.	0.9	82
477	Identification of <i>LIV1</i> , a Putative Zinc Transporter Gene Responsible for HDACi-Induced Apoptosis, Using a Functional Gene Screen Approach. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 3108-3116.	4.1	14

#	ARTICLE	IF	CITATIONS
478	Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo. <i>Oral Oncology</i> , 2009, 45, 766-770.	1.5	13
479	Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer. <i>BMC Cancer</i> , 2009, 9, 69.	2.6	47
480	TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies. <i>European Journal of Pharmacology</i> , 2009, 625, 63-72.	3.5	163
482	Total Synthesis of the Bicyclic Depsipeptide HDAC Inhibitors Spiruchostatins A and B, 5-epi-spiruchostatin B, FK228 (FR901228) and Preliminary Evaluation of Their Biological Activity. <i>3.3 Chemistry - A European Journal</i> , 2009, 15, 11174-11186.		61
483	Pyridylalanine-Containing Hydroxamic Acids as Selective HDAC6 Inhibitors. <i>ChemMedChem</i> , 2009, 4, 283-290.	3.2	37
484	Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 879-889.	2.5	14
485	New drugs in the treatment of acute myeloid leukaemia. <i>Memo - Magazine of European Medical Oncology</i> , 2009, 2, 75-79.	0.5	1
486	Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages. <i>Archives of Pharmacal Research</i> , 2009, 32, 613-624.	6.3	66
487	Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 381-389.	2.3	26
488	Hydroxyurea and hydroxamic acid derivatives as antitumor drugs. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 213-221.	2.3	106
489	DNER, an Epigenetically Modulated Gene, Regulates Glioblastoma-Derived Neurosphere Cell Differentiation and Tumor Propagation. <i>Stem Cells</i> , 2009, 27, 1473-1486.	3.2	84
490	Histone post-translational modifications by HPLC-ESI/MS after HT29 cell treatment with histone deacetylase inhibitors. <i>Proteomics</i> , 2009, 9, 5437-5445.	2.2	25
491	Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. <i>Cell Research</i> , 2009, 19, 1079-1089.	12.0	27
492	Using histone deacetylase inhibitors to enhance Foxp3 ⁺ regulatory T cell function and induce allograft tolerance. <i>Immunology and Cell Biology</i> , 2009, 87, 195-202.	2.3	81
493	Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3 ⁺ regulatory T cells. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 969-981.	46.4	163
494	Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. <i>Oncogene</i> , 2009, 28, 184-194.	5.9	128
495	Effects of Sodium Butyrate on Cell Death Induced by Photodynamic Therapy in U373MG and D54MG Astrocytoma Cell Lines. <i>Photochemistry and Photobiology</i> , 2009, 85, 1182-1188.	2.5	6
496	Design and synthesis of novel histone deacetylase inhibitor derived from nuclear localization signal peptide. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6588-6590.	2.2	12

#	ARTICLE	IF	CITATIONS
497	HDAC inhibitors in leukemia: Current status and perspectives. <i>Leukemia Research</i> , 2009, 33, 207-208.	0.8	8
498	3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 2868-2876.	5.5	43
499	Synthesis and Histone Deacetylase Inhibitory Activity of Largazole Analogs: Alteration of the Zinc-Binding Domain and Macrocyclic Scaffold. <i>Organic Letters</i> , 2009, 11, 1301-1304.	4.6	103
500	Expression and Function of Histone Deacetylases in Rheumatoid Arthritis Synovial Fibroblasts. <i>Journal of Rheumatology</i> , 2009, 36, 1580-1589.	2.0	101
501	Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 16-20.	2.8	19
502	HDACi " Targets beyond chromatin. <i>Cancer Letters</i> , 2009, 280, 160-167.	7.2	146
503	Differential effects of valproic acid on growth, proliferation and metastasis in HTB5 and HTB9 bladder cancer cell lines. <i>Cancer Letters</i> , 2009, 281, 196-202.	7.2	15
504	Tissue context-activated telomerase in human epidermis correlates with little age-dependent telomere loss. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2009, 1792, 297-308.	3.8	32
505	Ageing and liver regeneration. <i>Trends in Endocrinology and Metabolism</i> , 2009, 20, 171-176.	7.1	171
506	Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model. <i>Transplant Immunology</i> , 2009, 21, 198-202.	1.2	24
507	Antitumour activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2009, 38, 427.	1.5	0
508	Pharmacologic and Chemical Adjuvants in Tumor Virotherapy. <i>Chemical Reviews</i> , 2009, 109, 3125-3140.	47.7	52
509	Toxicity of Targeted Therapy in Non-Small-Cell Lung Cancer Management. <i>Clinical Lung Cancer</i> , 2009, 10, 28-35.	2.6	76
510	The combination effect of sodium butyrate and 5-Aza-2'-deoxycytidine on radiosensitivity in RKO colorectal cancer and MCF-7 breast cancer cell lines. <i>World Journal of Surgical Oncology</i> , 2009, 7, 49.	1.9	30
511	Discovery, biological activity, synthesis and potential therapeutic utility of naturally occurring histone deacetylase inhibitors. <i>Natural Product Reports</i> , 2009, 26, 1293.	10.3	63
512	Recent Advances in the Development of Polyamine Analogues as Antitumor Agents. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4551-4573.	6.4	153
513	Acetylation of FoxO1 Activates Bim Expression to Induce Apoptosis in Response to Histone Deacetylase Inhibitor Depsipeptide Treatment. <i>Neoplasia</i> , 2009, 11, 313-IN1.	5.3	102
514	Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis. <i>Autoimmunity</i> , 2009, 42, 120-125.	2.6	14

#	ARTICLE	IF	CITATIONS
515	Epigenetic Dysregulation in Cancer. <i>American Journal of Pathology</i> , 2009, 175, 1353-1361.	3.8	70
516	Novel Inhibitors of Human Histone Deacetylase (HDAC) Identified by QSAR Modeling of Known Inhibitors, Virtual Screening, and Experimental Validation. <i>Journal of Chemical Information and Modeling</i> , 2009, 49, 461-476.	5.4	99
517	Epigenetics in cancer: Targeting chromatin modifications. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1409-1420.	4.1	435
518	Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy. <i>Current Genomics</i> , 2009, 10, 336-352.	1.6	68
519	TRAIL Gene Therapy: From Preclinical Development to Clinical Application. <i>Current Gene Therapy</i> , 2009, 9, 9-19.	2.0	84
520	Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis. <i>Modern Rheumatology</i> , 2010, 20, 11-17.	1.8	73
521	Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts. <i>Development (Cambridge)</i> , 2010, 137, 1075-1084.	2.5	85
522	Upregulated Histone Deacetylase 1 Expression in Pancreatic Ductal Adenocarcinoma and Specific SiRNA Inhibits the Growth of Cancer Cells. <i>Pancreas</i> , 2010, 39, 994-1001.	1.1	12
523	Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2286-2297.	6.4	16
524	Identification of type-specific anticancer histone deacetylase inhibitors: road to success. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 625-633.	2.3	41
525	Inhibition of Histone Deacetylase 10 Induces Thioredoxin-Interacting Protein and Causes Accumulation of Reactive Oxygen Species in SNU-620 Human Gastric Cancer Cells. <i>Molecules and Cells</i> , 2010, 30, 107-112.	2.6	66
526	Proteinases involved in matrix turnover during cartilage and bone breakdown. <i>Cell and Tissue Research</i> , 2010, 339, 221-235.	2.9	131
527	Design of a novel nucleoside analog as potent inhibitor of the NAD ⁺ dependent deacetylase, SIRT2. <i>Systems and Synthetic Biology</i> , 2010, 4, 257-263.	1.0	8
528	Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer. <i>Molecular and Cellular Biochemistry</i> , 2010, 343, 163-171.	3.1	29
529	Alleviation of osteoarthritis by Trichostatin A, a histone deacetylase inhibitor, in experimental osteoarthritis. <i>Molecular Biology Reports</i> , 2010, 37, 3967-3972.	2.3	58
530	DNA methylation changes in a human cell model of breast cancer progression. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2010, 688, 28-35.	1.0	26
531	Quinazolines as novel anti-inflammatory histone deacetylase inhibitors. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2010, 690, 81-88.	1.0	7
532	VPA-related axial skeletal defects and apoptosis: A proposed event cascade. <i>Reproductive Toxicology</i> , 2010, 29, 106-112.	2.9	16

#	ARTICLE	IF	CITATIONS
533	Downregulation of a tumor suppressor RECK by hypoxia through recruitment of HDAC1 and HIF-1 α to reverse HRE site in the promoter. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2010, 1803, 608-616.	4.1	49
534	Playing the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1805, 123-140.	7.4	96
535	The role of epigenetics in environmental and occupational carcinogenesis. <i>Chemico-Biological Interactions</i> , 2010, 188, 340-349.	4.0	53
536	Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. <i>Clinical Immunology</i> , 2010, 136, 348-363.	3.2	124
537	Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines. <i>Gynecologic Oncology</i> , 2010, 116, 126-130.	1.4	39
538	In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: Does timing matter?. <i>Gynecologic Oncology</i> , 2010, 119, 351-357.	1.4	25
539	3D-QSAR Study on Apicidin Inhibit Histone Deacetylase. <i>Chinese Journal of Chemistry</i> , 2003, 21, 1596-1607.	4.9	4
540	Synthesis of <i>N</i> -Hydroxycinnamides Capped with a Naturally Occurring Moiety as Inhibitors of Histone Deacetylase. <i>ChemMedChem</i> , 2010, 5, 598-607.	3.2	38
541	A Structure-Based Virtual Screening Approach toward the Discovery of Histone Deacetylase Inhibitors: Identification of Promising Zinc-Chelating Groups. <i>ChemMedChem</i> , 2010, 5, 591-597.	3.2	44
542	Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat. <i>Electrophoresis</i> , 2010, 31, 2714-2721.	2.4	13
543	Inhibitors of Human Histone Deacetylase: Synthesis and Enzyme Assay of Hydroxamates with Piperazine Linker. <i>Archiv Der Pharmazie</i> , 2010, 343, 167-172.	4.1	7
544	Epigenetic cancer therapy: Proof of concept and remaining challenges. <i>BioEssays</i> , 2010, 32, 949-957.	2.5	67
545	NAD ⁺ -dependent histone deacetylases (sirtuins) as novel therapeutic targets. <i>Medicinal Research Reviews</i> , 2010, 30, 861-889.	10.5	80
546	Histone deacetylase inhibitors: synthesis of cyclic tetrapeptides and their triazole analogs. <i>Tetrahedron Letters</i> , 2010, 51, 4357-4360.	1.4	11
547	Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylase based on a cinnamic hydroxamic acid core structure. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5950-5964.	3.0	40
548	Discovery of 1H-benzo[d][1,2,3]triazol-1-yl 3,4,5-trimethoxybenzoate as a potential antiproliferative agent by inhibiting histone deacetylase. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 8457-8462.	3.0	40
549	SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 2044-2047.	2.2	55
550	Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 294-298.	2.2	15

#	ARTICLE	IF	CITATIONS
551	Vitamin D stimulates apoptosis in gastric cancer cells in synergy with trichostatin A/sodium butyrate-induced and 5-aza-2'-deoxycytidine-induced PTEN upregulation. <i>FEBS Journal</i> , 2010, 277, 989-999.	4.7	83
552	Histone deacetylase inhibitor enhances sensitivity of non-small cell lung cancer cells to 5-FU via down-regulation of thymidylate synthase expression and up-regulation of p21 ^{waf1/cip1} expression. <i>Cancer Science</i> , 2010, 101, 1424-1430.	3.9	40
553	The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. <i>British Journal of Haematology</i> , 2010, 149, 518-528.	2.5	78
554	An HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis. <i>Oncogene</i> , 2010, 29, 2659-2671.	5.9	17
555	Ubiquitin B: an essential mediator of trichostatin A-induced tumor-selective killing in human cancer cells. <i>Cell Death and Differentiation</i> , 2010, 17, 109-118.	11.2	22
556	Anti-Tumor Effect in Human Lung Cancer by a Combination Treatment of Novel Histone Deacetylase Inhibitors: SL142 or SL325 and Retinoic Acids. <i>PLoS ONE</i> , 2010, 5, e13834.	2.5	25
557	Overview of Histone Deacetylase Inhibitors in Haematological Malignancies. <i>Pharmaceuticals</i> , 2010, 3, 2674-2688.	3.8	7
559	Suppression of Neurotensin Receptor Type 1 Expression and Function by Histone Deacetylase Inhibitors in Human Colorectal Cancers. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2389-2398.	4.1	28
560	Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. <i>Human Molecular Genetics</i> , 2010, 19, 454-467.	2.9	110
561	Is There a Future for Histone Deacetylase Inhibitors in the Pharmacotherapy of Psychiatric Disorders?. <i>Molecular Pharmacology</i> , 2010, 77, 126-135.	2.3	162
562	Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 12617-12622.	7.1	179
563	Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 56-62.	1.6	259
564	Biotechnological potential of marine natural products. <i>Pure and Applied Chemistry</i> , 2010, 82, 17-26.	1.9	24
565	Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report. <i>Journal of Clinical Oncology</i> , 2010, 28, 3623-3629.	1.6	174
566	Histone Deacetylase Inhibition Attenuates Cell Growth with Associated Telomerase Inhibition in High-Grade Childhood Brain Tumor Cells. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2568-2581.	4.1	34
567	Interplay of bromodomain and histone acetylation in the regulation of p300-dependent genes. <i>Epigenetics</i> , 2010, 5, 509-515.	2.7	39
568	Effects of histone hyperacetylation on the preimplantation development of male and female bovine embryos. <i>Reproduction, Fertility and Development</i> , 2010, 22, 1041.	0.4	18
569	Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma. <i>Drugs</i> , 2010, 70, 273-286.	10.9	88

#	ARTICLE	IF	CITATIONS
570	The Role of Histone Deacetylase Inhibitors in the Treatment of Patients With Cutaneous T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 98-109.	0.4	25
571	Inhibition of HDAC9 Increases T Regulatory Cell Function and Prevents Colitis in Mice. <i>Gastroenterology</i> , 2010, 138, 583-594.	1.3	209
572	Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF- κ B p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. <i>Rheumatology</i> , 2010, 49, 1447-1460.	1.9	107
573	Epigenetics: A New Bridge between Nutrition and Health. <i>Advances in Nutrition</i> , 2010, 1, 8-16.	6.4	468
574	Epigenetic Targets and Cancer Drug Discovery. <i>Annual Reports in Medicinal Chemistry</i> , 2010, , 245-260.	0.9	0
575	Mass Spectrometry in Epigenetic Research. <i>Methods in Molecular Biology</i> , 2010, 593, 263-282.	0.9	13
576	Non-Peptide Macrocyclic Histone Deacetylase Inhibitors Derived from Tricyclic Ketolide Skeleton. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 6100-6111.	6.4	65
577	Molecular therapeutic approaches to melanoma. <i>Molecular Aspects of Medicine</i> , 2010, 31, 194-204.	6.4	28
578	Emerging molecular therapies of advanced thyroid cancer. <i>Molecular Aspects of Medicine</i> , 2010, 31, 215-226.	6.4	38
579	TRAIL receptor targeting therapies for non-small cell lung cancer: Current status and perspectives. <i>Drug Resistance Updates</i> , 2010, 13, 2-15.	14.4	69
580	Interplay between microRNAs and the epigenetic machinery: An intricate network. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2010, 1799, 694-701.	1.9	268
581	Inhibitors to understand molecular mechanisms of NAD ⁺ -dependent deacetylases (sirtuins). <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2010, 1799, 726-739.	1.9	57
582	Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction. <i>Transplant Immunology</i> , 2010, 23, 18-23.	1.2	36
583	(Bis)urea and (Bis)thiourea Inhibitors of Lysine-Specific Demethylase 1 as Epigenetic Modulators. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 5197-5212.	6.4	126
584	Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers. <i>Epigenomics</i> , 2010, 2, 9-38.	2.1	25
585	Inhibition of histone deacetylases by Trichostatin A leads to a HoxB4-independent increase of hematopoietic progenitor/stem cell frequencies as a result of selective survival. <i>Cytotherapy</i> , 2010, 12, 899-908.	0.7	4
587	Oxidative Stress, Thiol Redox Signaling Methods in Epigenetics. <i>Methods in Enzymology</i> , 2010, 474, 213-244.	1.0	28
588	Teratogenic mechanisms of medical drugs. <i>Human Reproduction Update</i> , 2010, 16, 378-394.	10.8	153

#	ARTICLE	IF	CITATIONS
589	Cancer epigenetics: above and beyond. <i>Toxicology Mechanisms and Methods</i> , 2011, 21, 275-288.	2.7	82
590	Pharmacoeugenetics: a new approach to predicting individual drug responses and targeting new drugs. <i>Pharmacological Reports</i> , 2011, 63, 293-304.	3.3	54
591	Synthesis and Characterization of SIRT6 Protein Coated Magnetic Beads: Identification of a Novel Inhibitor of SIRT6 Deacetylase from Medicinal Plant Extracts. <i>Analytical Chemistry</i> , 2011, 83, 7400-7407.	6.5	75
592	Does microglial dysfunction play a role in autism and Rett syndrome?. <i>Neuron Glia Biology</i> , 2011, 7, 85-97.	1.6	43
593	A new series of ferrocifen derivatives, bearing two aminoalkyl chains, with strong antiproliferative effects on breast cancer cells. <i>New Journal of Chemistry</i> , 2011, 35, 2212.	2.8	38
594	ERK1/2 activation plays important roles in the opposite effects of Trichostatin A in non-cancer and cancer cells. <i>Toxicol</i> , 2011, 57, 932-937.	1.6	12
595	Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance. <i>Molecular Pharmaceutics</i> , 2011, 8, 2021-2031.	4.6	110
596	New synthetic strategies towards psammalin A, access to natural product analogues for biological evaluation. <i>Organic and Biomolecular Chemistry</i> , 2011, 9, 659-662.	2.8	27
597	Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells. <i>Leukemia and Lymphoma</i> , 2011, 52, 1777-1786.	1.3	9
598	Elucidating the Mechanism of Regulation of Transforming Growth Factor β 2 Type II Receptor Expression in Human Lung Cancer Cell Lines. <i>Neoplasia</i> , 2011, 13, 912-917.	5.3	32
599	Mitochondrial-nuclear epistasis: Implications for human aging and longevity. <i>Ageing Research Reviews</i> , 2011, 10, 238-252.	10.9	53
601	Natural Products Synthesis: Enabling Tools To Penetrate Nature's Secrets of Biogenesis and Biomechanism. <i>Journal of Organic Chemistry</i> , 2011, 76, 4221-4259.	3.2	28
602	Nicotinamide Inhibits Growth of Carcinogen Induced Mouse Bladder Tumor and Human Bladder Tumor Xenograft Through Up-Regulation of RUNX3 and p300. <i>Journal of Urology</i> , 2011, 185, 2366-2375.	0.4	32
603	Pharmacokinetics, Safety and Inducible Cytokine Responses during a Phase 1 Trial of the Oral Histone Deacetylase Inhibitor ITF2357 (Civinostat). <i>Molecular Medicine</i> , 2011, 17, 353-362.	4.4	100
604	HDAC Inhibition and Graft Versus Host Disease. <i>Molecular Medicine</i> , 2011, 17, 404-416.	4.4	71
605	Epigenetic Therapies for Cancer. , 2011, , .		1
606	Chromatin Modifying Agents in the <i>In Vitro</i> Production of Bovine Embryos. <i>Veterinary Medicine International</i> , 2011, 2011, 1-9.	1.5	7
607	Epigenetic Changes in Melanoma and the Development of Epigenetic Therapy for Melanoma. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
608	Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 760-768.	1.5	34
609	Targeting Epigenetics through Histone Deacetylase Inhibitors in Acute Lymphoblastic Leukemia. <i>Current Cancer Drug Targets</i> , 2011, 11, 882-893.	1.6	14
610	Potential anti-cancer activity of N-(2-hydroxy-2-(2-naphthylthio) heptanamide (HNHA), a histone deacetylase inhibitor, against breast cancer both <i>in vitro</i> and <i>in vivo</i> . <i>Cancer Science</i> , 2011, 102, 343-350.	3.9	11
611	Intracellular signaling and hepatocellular carcinoma. <i>Seminars in Cancer Biology</i> , 2011, 21, 28-34.	9.6	65
612	Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma. <i>Oral Oncology</i> , 2011, 47, 1127-1133.	1.5	10
613	Differential immunotoxicity of histone deacetylase inhibitors on malignant and naïve hepatocytes. <i>Experimental and Toxicologic Pathology</i> , 2011, 63, 511-517.	2.1	6
614	HDAC inhibitor sodium butyrate sensitizes E1A+Ras-transformed cells to DNA damaging agents by facilitating formation and persistence of ³ H2AX foci. <i>Cancer Biology and Therapy</i> , 2011, 12, 1069-1077.	3.4	7
615	Histone Deacetylase Inhibitor: Antineoplastic Agent and Radiation Modulator. <i>Advances in Experimental Medicine and Biology</i> , 2011, 720, 171-179.	1.6	21
616	Concise, Convergent Syntheses of (±)-Trichostatin A Utilizing a Pd-Catalyzed Ketone Enolate α -Alkenylation Reaction. <i>Organic Letters</i> , 2011, 13, 3564-3567.	4.6	25
617	From bench to bedside: Targeting epigenetics for cancer therapy. <i>Clinical Oncology and Cancer Research</i> , 2011, 8, 191-201.	0.1	1
618	Sodium butyrate induces cell senescence in transformed rodent cells resistant to apoptosis. <i>Cell and Tissue Biology</i> , 2011, 5, 235-242.	0.4	2
619	Reduced Expression of Reelin (RELN) Gene Is Associated With High Recurrence Rate of Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 572-579.	1.5	49
620	A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. <i>Investigational New Drugs</i> , 2011, 29, 1004-1012.	2.6	38
621	Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 11-17.	3.3	64
622	Suffocating cancer: hypoxia-associated epimutations as targets for cancer therapy. <i>Clinical Epigenetics</i> , 2011, 3, 9.	4.1	17
623	Protein acetylation within the cellular response to radiation. <i>Journal of Cellular Physiology</i> , 2011, 226, 962-967.	4.1	20
624	Novel Cinnamyl Hydroxyamides and α -Aminoanilides as Histone Deacetylase Inhibitors: Apoptotic Induction and Cytodifferentiation Activity. <i>ChemMedChem</i> , 2011, 6, 698-712.	3.2	17
625	Carbamate Prodrug Concept for Hydroxamate HDAC Inhibitors. <i>ChemMedChem</i> , 2011, 6, 1193-1198.	3.2	37

#	ARTICLE	IF	CITATIONS
626	Histone deacetylase inhibition as an anticancer telomerase-targeting strategy. <i>International Journal of Cancer</i> , 2011, 129, 2765-2774.	5.1	16
628	Targeting Histone Lysine Demethylases by Truncating the Histone H3 Tail to Obtain Selective Substrate-Based Inhibitors. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 9100-9103.	13.8	39
629	Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival. <i>Leukemia Research</i> , 2011, 35, 620-625.	0.8	28
630	Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway. <i>Molecular Cancer Research</i> , 2011, 9, 516-527.	3.4	47
631	Direct Conversion of <i>C. elegans</i> Germ Cells into Specific Neuron Types. <i>Science</i> , 2011, 331, 304-308.	12.6	219
632	Overexpression of histone variant H2A.1 and cellular transformation are related in N-nitrosodiethylamine-induced sequential hepatocarcinogenesis. <i>Experimental Biology and Medicine</i> , 2011, 236, 30-35.	2.4	24
633	Deacetylation of Nonhistone Proteins by HDACs and the Implications in Cancer. <i>Handbook of Experimental Pharmacology</i> , 2011, 206, 39-56.	1.8	86
634	Valproic Acid Attenuates Proteinuria and Kidney Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1863-1875.	6.1	109
635	Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 4141-4146.	7.1	98
636	Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-17.	3.0	68
637	C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and β -tubulin hyperacetylation both in vitro and in vivo. <i>Cell Death and Disease</i> , 2011, 2, e117-e117.	6.3	61
638	Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer. <i>Cancers</i> , 2011, 3, 603-620.	3.7	11
639	Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas. <i>Korean Journal of Pathology</i> , 2012, 46, 142.	1.3	28
640	Nucleophilic Mechanism of ROS/RNS Signaling in Cancer Epigenetic Modifications. <i>American Journal of Biomedical Sciences</i> , 0, , 285-306.	0.2	3
641	The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin. <i>Clinical Cancer Research</i> , 2012, 18, 2230-2239.	7.0	16
642	Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis. <i>Acta Biochimica Et Biophysica Sinica</i> , 2012, 44, 80-91.	2.0	27
643	Spiruchostatin A Inhibits Proliferation and Differentiation of Fibroblasts from Patients with Pulmonary Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2012, 46, 687-694.	2.9	57
644	Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 182-186.	1.7	4

#	ARTICLE	IF	CITATIONS
645	Activation of systemic antitumor immunity via TRAIL-induced apoptosis. <i>Oncolmmunology</i> , 2012, 1, 1178-1180.	4.6	4
646	DNA Methylation Profiling Identifies Global Methylation Differences and Markers of Adrenocortical Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1004-E1013.	3.6	98
647	Nuclear Smad7 Overexpressed in Mesenchymal Cells Acts as a Transcriptional Corepressor by Interacting with HDAC-1 and E2F to Regulate Cell Cycle. <i>Biology Open</i> , 2012, 1, 247-260.	1.2	14
648	Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 463-480.	3.4	17
649	Nanomedicine: pharmacological perspectives. <i>Nanotechnology Reviews</i> , 2012, 1, .	5.8	14
650	Intrinsic and Extrinsic Apoptotic Pathway Signaling as Determinants of Histone Deacetylase Inhibitor Antitumor Activity. <i>Advances in Cancer Research</i> , 2012, 116, 165-197.	5.0	101
651	Overview of the Classical Histone Deacetylase Enzymes and Histone Deacetylase Inhibitors. , 2012, 2012, 1-12.		12
652	Controversies Surrounding the Potential Use of Histone Deacetylase Inhibitors for the Treatment of Asthma. <i>ISRN Pulmonology</i> , 2012, 2012, 1-10.	0.3	1
653	Editorial: HDAC inhibition begets more MDSCs. <i>Journal of Leukocyte Biology</i> , 2012, 91, 679-681.	3.3	5
654	The acetylation of transcription factor HBP1 by p300/CBP enhances p16INK4A expression. <i>Nucleic Acids Research</i> , 2012, 40, 981-995.	14.5	42
655	Epithelialâ€mesenchymal transition in pulmonary carcinosarcoma: case report and literature review. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 31-37.	3.2	17
656	Histone Deacetylase Inhibitors Globally Enhance H3/H4 Tail Acetylation Without Affecting H3 Lysine 56 Acetylation. <i>Scientific Reports</i> , 2012, 2, 220.	3.3	70
657	Valproic Acid Inhibits Angiogenesis In Vitro and Glioma Angiogenesis In Vivo in the Brain. <i>Neurologia Medico-Chirurgica</i> , 2012, 52, 186-193.	2.2	58
658	Defining the Mechanism of Action and Enzymatic Selectivity of Psammaplin A against Its Epigenetic Targets. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1731-1750.	6.4	89
659	HDAC Inhibitors. <i>Advances in Cancer Research</i> , 2012, 116, 87-129.	5.0	114
660	Polyamine-based small molecule epigenetic modulators. <i>MedChemComm</i> , 2012, 3, 14-21.	3.4	32
661	Common Fragile Sites: Genomic Hotspots of DNA Damage and Carcinogenesis. <i>International Journal of Molecular Sciences</i> , 2012, 13, 11974-11999.	4.1	60
662	Estradiol receptors in breast cancer cells: Associated co-factors as targets for new therapeutic approaches. <i>Steroids</i> , 2012, 77, 1249-1261.	1.8	27

#	ARTICLE	IF	CITATIONS
663	Anti-cancer potential of selenium- and tellurium-containing species: opportunities abound!. Applied Organometallic Chemistry, 2012, 26, 655-662.	3.5	54
664	A Sensitive Electrochemical Biosensor for Detection of Histone Deacetylase Activity Using an Acetylated Peptide. Electroanalysis, 2012, 24, 2365-2370.	2.9	9
665	Co-location of HDAC2 and Insulin Signaling Components in the Adult Mouse Hippocampus. Cellular and Molecular Neurobiology, 2012, 32, 1337-1342.	3.3	15
666	HDACI-induced thrombocytopenia is caused by its unexpected target. Experimental Hematology, 2012, 40, 695-697.	0.4	3
667	Synergetic toxicity of DATR, a recombinant soluble human TRAIL mutant, in combination with traditional chemotherapeutics in rats. Regulatory Toxicology and Pharmacology, 2012, 64, 361-366.	2.7	2
668	Histone Deacetylases and Their Role in Asthma. Journal of Asthma, 2012, 49, 121-128.	1.7	28
669	Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors. Expert Review of Hematology, 2012, 5, 303-311.	2.2	11
670	Histone Deacetylase Inhibition by Sodium Valproate Regulates Polarization of Macrophage Subsets. DNA and Cell Biology, 2012, 31, 592-599.	1.9	49
671	Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer. Nature Reviews Cancer, 2012, 12, 709-720.	28.4	181
672	Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Medicinal Chemistry, 2012, 4, 1439-1460.	2.3	144
673	Loss of Epigenetic Modification Driven by the Foxp3 Transcription Factor Leads to Regulatory T Cell Insufficiency. Immunity, 2012, 36, 717-730.	14.3	139
674	Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma. Journal of Pediatric Surgery, 2012, 47, 1267-1271.	1.6	12
675	Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells. Biochemical and Biophysical Research Communications, 2012, 420, 325-330.	2.1	18
676	Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing Family Tumors. Cancer Letters, 2012, 320, 14-22.	7.2	32
677	Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications. Cancer Treatment Reviews, 2012, 38, 36-53.	7.7	57
678	Brazilin Induces Apoptosis and G2/M Arrest via Inactivation of Histone Deacetylase in Multiple Myeloma U266 Cells. Journal of Agricultural and Food Chemistry, 2012, 60, 9882-9889.	5.2	66
679	Enhancing the anticancer effect of the histone deacetylase inhibitor by activating transglutaminase. European Journal of Cancer, 2012, 48, 3278-3287.	2.8	15
680	Influence of Natural and Synthetic Histone Deacetylase Inhibitors on Chromatin. Antioxidants and Redox Signaling, 2012, 17, 340-354.	5.4	15

#	ARTICLE	IF	CITATIONS
681	Low Molecular Weight Amidoximes that Act as Potent Inhibitors of Lysine-Specific Demethylase 1. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7378-7391.	6.4	68
682	Butyrate-induced GPR41 Activation Inhibits Histone Acetylation and Cell Growth. <i>Journal of Genetics and Genomics</i> , 2012, 39, 375-384.	3.9	58
683	Discovery and activity profiling of thailandepsins A through F, potent histone deacetylase inhibitors, from <i>Burkholderia thailandensis</i> E264. <i>MedChemComm</i> , 2012, 3, 976.	3.4	38
685	Inhibition of Histone Deacetylase Activity in Human Endometrial Stromal Cells Promotes Extracellular Matrix Remodelling and Limits Embryo Invasion. <i>PLoS ONE</i> , 2012, 7, e30508.	2.5	53
686	Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models. <i>PLoS ONE</i> , 2012, 7, e30815.	2.5	158
687	Linking Yeast Gcn5p Catalytic Function and Gene Regulation Using a Quantitative, Graded Dominant Mutant Approach. <i>PLoS ONE</i> , 2012, 7, e36193.	2.5	12
688	Valproic Acid Downregulates RBP4 and Elicits Hypervitaminosis A-Teratogenesis—A Kinetic Analysis on Retinol/Retinoic Acid Homeostatic System. <i>PLoS ONE</i> , 2012, 7, e43692.	2.5	19
689	Epigenetic mechanisms of plant-derived anticancer drugs. <i>Frontiers in Bioscience - Landmark</i> , 2012, 17, 129.	3.0	46
690	Epigenetics and the Developmental Origins of Inflammatory Bowel Diseases. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 909-915.	1.7	60
691	Epigenetics Modifications and Therapeutic Prospects in Human Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 2012, 3, 40.	3.5	37
692	Synthesis, evaluation and molecular modeling of cyclic tetrapeptide histone deacetylase inhibitors as anticancer agents. <i>Journal of Peptide Science</i> , 2012, 18, 242-251.	1.4	13
693	Molecular markers of adrenocortical tumors. <i>Journal of Surgical Oncology</i> , 2012, 106, 549-556.	1.7	14
694	HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 2167-2177.	2.6	98
695	TSA-induced JMJD2B downregulation is associated with cyclin B1-dependent survivin degradation and apoptosis in LNCap cells. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 2375-2382.	2.6	17
696	Binding free energy calculations and biological testing of novel thiobarbiturates as inhibitors of the human NAD ⁺ dependent histone deacetylase Sirt2. <i>MedChemComm</i> , 2012, 3, 167-173.	3.4	33
697	HDAC6 at the Intersection of Neuroprotection and Neurodegeneration. <i>Traffic</i> , 2012, 13, 771-779.	2.7	63
698	Multiple point action mechanism of valproic acid-teratogenicity alleviated by folic acid, vitamin C, And N-acetylcysteine in chicken embryo model. <i>Toxicology</i> , 2012, 291, 32-42.	4.2	29
699	Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2012, 130, 694-704.	5.1	47

#	ARTICLE	IF	CITATIONS
700	Discovery of a novel histone deacetylase 8 inhibitor by virtual screening. <i>Medicinal Chemistry Research</i> , 2012, 21, 152-156.	2.4	19
701	Application of Epigenome-Modifying Small Molecules in Induced Pluripotent Stem Cells. <i>Medicinal Research Reviews</i> , 2013, 33, 790-822.	10.5	14
702	Histone de-acetylase inhibitors: a promising future for cancer treatment?. <i>Infectious Agents and Cancer</i> , 2013, 8, 10.	2.6	1
703	HDAC inhibitors in experimental liver and kidney fibrosis. <i>Fibrogenesis and Tissue Repair</i> , 2013, 6, 1.	3.4	71
704	Design, synthesis, and biological evaluation of novel histone deacetylase 1 inhibitors through click chemistry. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3295-3299.	2.2	18
705	Photodynamic therapeutic effect of indocyanine green entrapped in polymeric nanoparticles and their anti-EGFR-conjugate in skin cancer in CD1 mice. <i>Photodiagnosis and Photodynamic Therapy</i> , 2013, 10, 446-459.	2.6	30
706	Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines. <i>Cellular Oncology (Dordrecht)</i> , 2013, 36, 351-362.	4.4	11
707	A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A children's oncology group phase 1 consortium study. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1452-1457.	1.5	68
708	Deregulated Chromatin Remodeling in the Pathobiology of Brain Tumors. <i>NeuroMolecular Medicine</i> , 2013, 15, 1-24.	3.4	19
709	A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 974-985.	2.6	28
710	Microbial natural products: molecular blueprints for antitumor drugs. <i>Journal of Industrial Microbiology and Biotechnology</i> , 2013, 40, 1181-1210.	3.0	60
711	Zinc in Biology. , 2013, , 179-205.		1
712	Histone deacetylase inhibitors suppress mechanical stress-induced expression of RUNX-2 and ADAMTS-5 through the inhibition of the MAPK signaling pathway in cultured human chondrocytes. <i>Osteoarthritis and Cartilage</i> , 2013, 21, 165-174.	1.3	61
713	Molecular pathways and potential therapeutic targets in glioblastoma multiforme. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1307-1318.	2.4	5
714	Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. <i>Cancers</i> , 2013, 5, 919-942.	3.7	37
715	In vivo effects of Trichostatin A " A histone deacetylase inhibitor " On chromatin remodeling during <i>Triturus cristatus</i> spermatogenesis. <i>Animal Reproduction Science</i> , 2013, 142, 89-99.	1.5	8
716	Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. <i>Lancet Oncology</i> , The, 2013, 14, e302-e309.	10.7	76
717	Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis. <i>Toxicology and Applied Pharmacology</i> , 2013, 271, 276-284.	2.8	54

#	ARTICLE	IF	CITATIONS
718	Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects. <i>International Immunopharmacology</i> , 2013, 16, 72-78.	3.8	110
719	Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents. <i>European Journal of Medicinal Chemistry</i> , 2013, 70, 477-486.	5.5	44
720	New histone deacetylase inhibitors based on 4-fluoro-2-amino acid esters: Synthesis and activity. <i>Journal of Fluorine Chemistry</i> , 2013, 152, 144-156.	1.7	12
721	Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. <i>Investigational New Drugs</i> , 2013, 31, 39-45.	2.6	32
722	Biological Evaluation of New Largazole Analogues: Alteration of Macrocyclic Scaffold with Click Chemistry. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 132-136.	2.8	36
723	Targeting histone deacetylase in thyroid cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 179-193.	3.4	25
724	Discovery of Pyridone-Based Histone Deacetylase Inhibitors: Approaches for Metabolic Stability. <i>ChemMedChem</i> , 2013, 8, 272-279.	3.2	19
725	Evolution of Concise and Flexible Synthetic Strategies for Trichostatic Acid and the Potent Histone Deacetylase Inhibitor Trichostatin A. <i>European Journal of Organic Chemistry</i> , 2013, 2013, 162-172.	2.4	13
726	Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 966-971.	7.1	66
727	HDAC7 Inhibits Osteoclastogenesis by Reversing RANKL-Triggered β -Catenin Switch. <i>Molecular Endocrinology</i> , 2013, 27, 325-335.	3.7	40
728	Highly Ligand Efficient and Selective <i>N</i> -(2-(Thioethyl)picolinamide) Histone Deacetylase Inhibitors Inspired by the Natural Product Psammoplin...A. <i>ChemMedChem</i> , 2013, 8, 149-156.	3.2	17
729	Molecular modelling studies of Histone Deacetylase inhibitors as anticancer agents. <i>Journal of Pharmacy Research</i> , 2013, 7, 611-620.	0.4	0
730	A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 407-415.	5.6	20
731	The role of epigenetics in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2013, 81, 311-318.	2.0	51
732	Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases. <i>Journal of Nutritional Biochemistry</i> , 2013, 24, 977-985.	4.2	92
733	Design, synthesis and bioevaluation of novel benzamides derivatives as HDAC inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 179-182.	2.2	6
734	HDAC inhibition decreases XIST expression on female IVP bovine blastocysts. <i>Reproduction</i> , 2013, 145, 9-17.	2.6	17
735	Histone Deacetylase Inhibitors. <i>Clinical Journal of Oncology Nursing</i> , 2013, 17, 34-40.	0.6	15

#	ARTICLE	IF	CITATIONS
736	A Diamond Nanoneedle Array for Potential High-Throughput Intracellular Delivery. <i>Advanced Healthcare Materials</i> , 2013, 2, 1103-1107.	7.6	38
737	Pediatric Relapsed or Refractory Leukemia: New Pharmacotherapeutic Developments and Future Directions. <i>Drugs</i> , 2013, 73, 439-461.	10.9	10
738	Epigenetics: A novel therapeutic approach for the treatment of Alzheimer's disease. , 2013, 139, 41-50.		95
739	Reactive Oxygen Species, Kinase Signaling, and Redox Regulation of Epigenetics. , 2013, , 309-342.		0
740	A novel two-step QSAR modeling work flow to predict selectivity and activity of HDAC inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 929-933.	2.2	29
741	Different effect of sodium butyrate on cancer and normal prostate cells. <i>Toxicology in Vitro</i> , 2013, 27, 1489-1495.	2.4	19
742	Mechanisms of G1 cell cycle arrest and apoptosis in myeloma cells induced by hybrid-compound histone deacetylase inhibitor. <i>Biochemical and Biophysical Research Communications</i> , 2013, 434, 413-420.	2.1	15
743	Combination therapy: Histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. <i>Cancer Letters</i> , 2013, 329, 1-8.	7.2	87
744	Monofunctional and Higher-Valent Platinum Anticancer Agents. <i>Inorganic Chemistry</i> , 2013, 52, 12234-12249.	4.0	199
745	HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. <i>Cell Death and Disease</i> , 2013, 4, e519-e519.	6.3	150
746	Santacruzamate A, a Potent and Selective Histone Deacetylase Inhibitor from the Panamanian Marine Cyanobacterium cf. <i>Symploca</i> sp.. <i>Journal of Natural Products</i> , 2013, 76, 2026-2033.	3.0	64
747	Oxidative Stress and Chromatin Remodeling in Chronic Obstructive Pulmonary Disease and Smoking-Related Diseases. <i>Antioxidants and Redox Signaling</i> , 2013, 18, 1956-1971.	5.4	153
748	Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk. <i>Carcinogenesis</i> , 2013, 34, 1012-1017.	2.8	29
749	Titration and hysteresis in epigenetic chromatin silencing. <i>Physical Biology</i> , 2013, 10, 036005.	1.8	16
750	Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies. <i>Journal of Experimental Medicine</i> , 2013, 210, 647-653.	8.5	73
751	Synergistic combination of valproic acid and oncolytic parvovirus Δ VP as a potential therapy against cervical and pancreatic carcinomas. <i>EMBO Molecular Medicine</i> , 2013, 5, 1537-1555.	6.9	55
752	Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2709-2721.	4.1	45
753	Silibinin Synergizes with Histone Deacetylase and DNA Methyltransferase Inhibitors in Upregulating E-cadherin Expression Together with Inhibition of Migration and Invasion of Human Non-small Cell Lung Cancer Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 345, 206-214.	2.5	75

#	ARTICLE	IF	CITATIONS
754	Supplementation with the histone deacetylase inhibitor trichostatin A during in vitro culture of bovine embryos. <i>Zygote</i> , 2013, 21, 59-63.	1.1	3
755	Loss of <i>Hfe</i> Leads to Progression of Tumor Phenotype in Primary Retinal Pigment Epithelial Cells. <i>PLoS ONE</i> , 2013, 8, e71663.	2.5	11
756	From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1441-1456.	6.3	51
757	MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. <i>Blood</i> , 2013, 121, 4115-4125.	1.4	69
758	Effects of Trichostatin A in a Rat Model of Acute Graft-Versus-Host Disease After Liver Transplantation. <i>Transplantation</i> , 2013, 96, 25-33.	1.0	6
759	Thioester derivatives of the natural product psammoplin A as potent histone deacetylase inhibitors. <i>Beilstein Journal of Organic Chemistry</i> , 2013, 9, 81-88.	2.2	28
760	Effects of cisplatin and panobinostat on human mesothelial (Met-5A) and malignant pleural mesothelioma (MSTO-211H) cells. <i>Genetics and Molecular Research</i> , 2013, 12, 5405-5413.	0.2	5
761	RuvBL2 Is Involved in Histone Deacetylase Inhibitor PCI-24781-Induced Cell Death in SK-N-DZ Neuroblastoma Cells. <i>PLoS ONE</i> , 2013, 8, e71663.	2.5	11
762	Trichostatin A Promotes the Generation and Suppressive Functions of Regulatory T Cells. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.	3.3	19
763	Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2014, 25, 249.	2.2	31
764	Inhibition of HDAC1 and DNMT1 Modulate RGS10 Expression and Decrease Ovarian Cancer Chemoresistance. <i>PLoS ONE</i> , 2014, 9, e87455.	2.5	80
765	Iron Complexation to Histone Deacetylase Inhibitors SAHA and LAQ824 in PEGylated Liposomes Can Considerably Improve Pharmacokinetics in Rats. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2014, 17, 583.	2.1	7
766	Protein post-translational modifications and regulation of pluripotency in human stem cells. <i>Cell Research</i> , 2014, 24, 143-160.	12.0	282
767	Calcium butyrate: Anti-inflammatory effect on experimental colitis in rats and antitumor properties. <i>Biomedical Reports</i> , 2014, 2, 559-563.	2.0	15
768	Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes. <i>PLoS Pathogens</i> , 2014, 10, e1004287.	4.7	179
769	Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro. <i>Oncology Letters</i> , 2014, 7, 203-208.	1.8	20
770	Oncogenic STRAP functions as a novel negative regulator of E-cadherin and p21 ^{Cip1} by modulating the transcription factor Sp1. <i>Cell Cycle</i> , 2014, 13, 3909-3920.	2.6	21
771	Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. <i>Pediatric Blood and Cancer</i> , 2014, 61, 245-252.	1.5	37

#	ARTICLE	IF	CITATIONS
772	Potential role of histone deacetylase inhibitors in the treatment of advanced non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2014, 3, 255-261.	1.5	0
773	Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1979-1990.	4.1	49
774	Discovery of a series of hydroxamic acid derivatives as potent histone deacetylase inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2014, 29, 582-589.	5.2	6
775	Histone Deacetylase Inhibition with Valproic Acid Downregulates Osteocalcin Gene Expression in Human Dental Pulp Stem Cells and Osteoblasts: Evidence for HDAC2 Involvement. <i>Stem Cells</i> , 2014, 32, 279-289.	3.2	116
776	Butyrate protects liver against ischemia reperfusion injury by inhibiting nuclear factor kappa B activation in Kupffer cells. <i>Journal of Surgical Research</i> , 2014, 187, 653-659.	1.6	59
777	The promise and failures of epigenetic therapies for cancer treatment. <i>Cancer Treatment Reviews</i> , 2014, 40, 153-169.	7.7	76
778	Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes. <i>Journal of Molecular Medicine</i> , 2014, 92, 93-102.	3.9	28
779	Combined Analysis of Phenotypic and Target-Based Screening in Assay Networks. <i>Journal of Biomolecular Screening</i> , 2014, 19, 782-790.	2.6	23
780	Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2014, 131, 104-112.	3.8	14
781	Transcriptional Regulation of Endothelial Arginase 2 by Histone Deacetylase 2. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1556-1566.	2.4	55
782	Potent and Orally Efficacious Bisthiazole-Based Histone Deacetylase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 628-633.	2.8	30
783	Design of small molecule epigenetic modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 21-32.	2.2	31
784	Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2014, 68, 327-334.	5.6	63
785	Synthesis and anticancer activities of thieno[3,2-d]pyrimidines as novel HDAC inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 358-365.	3.0	23
786	Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 87-95.	10.7	113
787	Inhibition of autophagy induced by TSA sensitizes colon cancer cell to radiation. <i>Tumor Biology</i> , 2014, 35, 1003-1011.	1.8	27
788	Photo-Inducible Crosslinked Nanoassemblies for pH-Controlled Drug Release. <i>Pharmaceutical Research</i> , 2014, 31, 1254-1263.	3.5	8
789	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2014, 86, 639-652.	5.5	48

#	ARTICLE	IF	CITATIONS
790	Antitumor Action of a Novel Histone Deacetylase Inhibitor, YF479, in Breast Cancer. <i>Neoplasia</i> , 2014, 16, 665-677.	5.3	35
791	Synthesis, bioevaluation and docking study of 5-substitutedphenyl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2014, 29, 611-618.	5.2	31
792	Polysaccharide extracts of the brown alga <i>Sargassum asperifolium</i> possess in vitro cancer chemopreventive properties. <i>Natural Product Research</i> , 2014, 28, 2304-2311.	1.8	7
793	Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression. <i>International Journal of Cancer</i> , 2014, 135, 563-573.	5.1	56
794	A steered molecular dynamics mediated hit discovery for histone deacetylases. <i>Physical Chemistry Chemical Physics</i> , 2014, 16, 3777.	2.8	28
795	A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2014, 167, 185-193.	2.5	115
796	Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4768-4772.	2.2	12
797	Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 6146-6155.	3.0	24
798	Efforts towards the synthesis of microsporin B: ready access to both the enantiomers of the key amino acid fragment. <i>Tetrahedron Letters</i> , 2014, 55, 4777-4779.	1.4	7
799	The role of p21waf1/cip1 and p27Kip1 in HDACi-mediated tumor cell death and cell cycle arrest in the E1/4-myc model of B-cell lymphoma. <i>Oncogene</i> , 2014, 33, 5415-5423.	5.9	43
800	Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 673-691.	46.4	1,277
801	Discovery of a series of small molecules as potent histone deacetylase inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2014, 29, 333-337.	5.2	11
802	Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 469-478.	4.2	25
803	A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. <i>Leukemia and Lymphoma</i> , 2014, 55, 2301-2304.	1.3	61
804	Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells. <i>Journal of Dermatological Science</i> , 2014, 75, 140-147.	1.9	19
805	Epigenetic modulators mitigate angiogenesis through a complex transcriptomic network. <i>Vascular Pharmacology</i> , 2014, 60, 57-66.	2.1	21
806	Low oxygen atmosphere facilitates proliferation and maintains undifferentiated state of umbilical cord mesenchymal stem cells in an hypoxia inducible factor-dependent manner. <i>Cytotherapy</i> , 2014, 16, 881-892.	0.7	71
807	Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity. <i>Cytotherapy</i> , 2014, 16, 1431-1440.	0.7	25

#	ARTICLE	IF	CITATIONS
808	Design, synthesis, and biological evaluation of largazole derivatives: alteration of the zinc-binding domain. <i>Tetrahedron</i> , 2014, 70, 7763-7769.	1.9	14
809	CTSL2 is a pro-apoptotic target of E2F1 and a modulator of histone deacetylase inhibitor and DNA damage-induced apoptosis. <i>Oncogene</i> , 2014, 33, 1249-1257.	5.9	7
810	Teratogenic Mechanisms Associated with Prenatal Medication Exposure. <i>Therapie</i> , 2014, 69, 13-24.	1.0	15
811	Superior antimitogenic and chemosensitization activities of the combination treatment of the histone deacetylase inhibitor apicidin and proteasome inhibitors on human colorectal cancer cells. <i>International Journal of Oncology</i> , 2014, 44, 105-128.	3.3	8
812	HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population. <i>Oncology Reports</i> , 2015, 34, 2238-2250.	2.6	75
813	Positive Regulation of Interleukin-2 Expression by a Pseudokinase, Tribbles 1, in Activated T Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2015, 38, 1126-1133.	1.4	10
814	Suberoylanilide Hydroxamic Acid Treatment Reveals Crosstalks among Proteome, Ubiquitylome and Acetylome in Non-Small Cell Lung Cancer A549 Cell Line. <i>Scientific Reports</i> , 2015, 5, 9520.	3.3	78
816	Pharmacologic Activities of 3-Hydroxypterostilbene: Cytotoxic, Anti-Oxidant, Anti-Adipogenic, Anti-Inflammatory, Histone Deacetylase and Sirtuin 1 Inhibitory Activity. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2015, 18, 713.	2.1	11
817	The Effect of MGCD0103 on CYP450 Isoforms Activity of Rats by Cocktail Method. <i>BioMed Research International</i> , 2015, 2015, 1-7.	1.9	5
818	Ku70 is essential for histone deacetylase inhibitor trichostatin A-induced apoptosis. <i>Molecular Medicine Reports</i> , 2015, 12, 581-586.	2.4	5
819	The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming. <i>International Journal of Molecular Sciences</i> , 2015, 16, 18252-18269.	4.1	9
820	Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents. <i>Molecules</i> , 2015, 20, 3898-3941.	3.8	565
821	DMSO Efficiently Down Regulates Pluripotency Genes in Human Embryonic Stem Cells during Definitive Endoderm Derivation and Increases the Proficiency of Hepatic Differentiation. <i>PLoS ONE</i> , 2015, 10, e0117689.	2.5	54
822	Ectopic hox12 Expression Evoked by Histone Deacetylase Inhibition Disrupts Axial Specification of the Sea Urchin Embryo. <i>PLoS ONE</i> , 2015, 10, e0143860.	2.5	19
823	Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage. <i>Oncotarget</i> , 2015, 6, 9970-9984.	1.8	38
824	Treatment of chronic kidney diseases with histone deacetylase inhibitors. <i>Frontiers in Physiology</i> , 2015, 6, 121.	2.8	58
825	QT Prolongation and Oncology Drug Development. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 341-355.	1.7	34
826	QSAR Studies on Hydroxamic Acids: A Fascinating Family of Chemicals with a Wide Spectrum of Activities. <i>Chemical Reviews</i> , 2015, 115, 6427-6490.	47.7	40

#	ARTICLE	IF	CITATIONS
827	Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors. <i>Biomaterials</i> , 2015, 51, 208-215.	11.4	59
828	Unravelling the Complexity and Functions of MTA Coregulators in Human Cancer. <i>Advances in Cancer Research</i> , 2015, 127, 1-47.	5.0	27
829	Radiation-induced modulation of immunogenic genes in tumor cells is regulated by both histone deacetylases and DNA methyltransferases. <i>International Journal of Oncology</i> , 2015, 47, 2264-2275.	3.3	12
830	Histone deacetylase inhibitors in hematological malignancies and solid tumors. <i>Archives of Pharmacal Research</i> , 2015, 38, 933-949.	6.3	106
831	MicroRNA-222 regulates MMP-13 via targeting HDAC-4 during osteoarthritis pathogenesis. <i>BBA Clinical</i> , 2015, 3, 79-89.	4.1	78
832	Digging deep into "dirty" drugs modulation of the methylation machinery. <i>Drug Metabolism Reviews</i> , 2015, 47, 252-279.	3.6	63
833	Recent Advances in Cancer Therapeutics. <i>Progress in Medicinal Chemistry</i> , 2015, 54, 1-63.	10.4	32
834	Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial. <i>Cancer</i> , 2015, 121, 1654-1661.	4.1	39
835	Comparative Modeling and Benchmarking Data Sets for Human Histone Deacetylases and Sirtuin Families. <i>Journal of Chemical Information and Modeling</i> , 2015, 55, 374-388.	5.4	25
836	Natural Products as Zinc-Dependent Histone Deacetylase Inhibitors. <i>ChemMedChem</i> , 2015, 10, 441-450.	3.2	22
837	Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group. <i>MedChemComm</i> , 2015, 6, 613-618.	3.4	27
838	Fragment-Based Drug Discovery of 2-Thiazolidinones as BRD4 Inhibitors: 2. Structure-Based Optimization. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1281-1297.	6.4	50
839	QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review. <i>Targeted Oncology</i> , 2015, 10, 27-43.	3.6	20
840	Life Extension in <i>Drosophila</i> by Histone Deacetylase Inhibitors. <i>Healthy Ageing and Longevity</i> , 2015, , 245-264.	0.2	1
841	Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions. <i>Drugs</i> , 2015, 75, 1323-1334.	10.9	32
842	Epigenetic Therapy of Cancer. , 2015, , 325-358.		2
843	Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 3457-3471.	3.0	28
844	Emerging approaches for histone deacetylase inhibitor drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 599-613.	5.0	63

#	ARTICLE	IF	CITATIONS
845	TRPM2 Mediates Histone Deacetylase Inhibition-Induced Apoptosis in Bladder Cancer Cells. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 87-93.	1.0	17
846	Molecular Targets in the Treatment of Cardiac Hypertrophy. , 2015, , 343-371.		11
847	Thymosin α 24 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma. <i>Molecular Oncology</i> , 2015, 9, 1484-1500.	4.6	17
848	Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4812-4821.	6.4	36
849	1,3,4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2015, 97, 124-141.	5.5	142
850	A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 1566-1573.	7.0	76
851	A fluorescent histone deacetylase (HDAC) inhibitor for cellular imaging. <i>Chemical Communications</i> , 2015, 51, 7827-7830.	4.1	33
852	HDAC9 Inhibits Osteoclastogenesis via Mutual Suppression of PPAR γ /RANKL Signaling. <i>Molecular Endocrinology</i> , 2015, 29, 730-738.	3.7	55
853	Novel 2-oxoindoline-based hydroxamic acids: synthesis, cytotoxicity, and inhibition of histone deacetylation. <i>Tetrahedron Letters</i> , 2015, 56, 6425-6429.	1.4	12
854	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7672-7680.	6.4	49
855	Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2015, 74, 257-264.	5.6	44
856	Therapeutic applications of TRAIL receptor agonists in cancer and beyond. , 2015, 155, 117-131.		67
857	Drugs that Suppress Proliferation. , 2015, , 113-162.		2
858	A structure-activity relationship of non-peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-inflammatory activities. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7543-7564.	3.0	17
859	HDAC Inhibitors Target HDAC5, Upregulate MicroRNA-125a-5p, and Induce Apoptosis in Breast Cancer Cells. <i>Molecular Therapy</i> , 2015, 23, 656-666.	8.2	87
860	Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells. <i>Tumor Biology</i> , 2015, 36, 1471-1476.	1.8	4
861	HDAC inhibitor (S)-1 disrupts HDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 143-154.	3.6	25
862	Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 66-84.	5.4	58

#	ARTICLE	IF	CITATIONS
863	Epigenetic Modification of the Leptin Promoter in Diet-Induced Obese Mice and the Effects of N-3 Polyunsaturated Fatty Acids. <i>Scientific Reports</i> , 2014, 4, 5282.	3.3	74
864	Rational design and validation of a Tip60 histone acetyltransferase inhibitor. <i>Scientific Reports</i> , 2014, 4, 5372.	3.3	103
865	Benzotriazole: An overview on its versatile biological behavior. <i>European Journal of Medicinal Chemistry</i> , 2015, 97, 612-648.	5.5	148
866	Epigenetic Regulation of MicroRNAs Controlling CLDN14 Expression as a Mechanism for Renal Calcium Handling. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 663-676.	6.1	50
867	Arrhythmias and QTc Prolongations. , 2016, , 245-269.		0
868	Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment. <i>Journal of Cancer</i> , 2016, 7, 1497-1514.	2.5	71
869	Crosstalk among the proteome, lysine phosphorylation, and acetylation in romidepsin-treated colon cancer cells. <i>Oncotarget</i> , 2016, 7, 53471-53501.	1.8	7
870	Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia. <i>Genes and Cancer</i> , 2016, 7, 292-300.	1.9	19
871	Epigenetics in non-small cell lung cancer: from basics to therapeutics. <i>Translational Lung Cancer Research</i> , 2016, 5, 155-171.	2.8	121
872	Three-Dimensional Biologically Relevant Spectrum (BRS-3D): Shape Similarity Profile Based on PDB Ligands as Molecular Descriptors. <i>Molecules</i> , 2016, 21, 1554.	3.8	19
873	Modulating chromatin structure and DNA accessibility by deacetylase inhibition enhances the anti-cancer activity of silver nanoparticles. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 146, 670-677.	5.0	38
874	Loss of histone deacetylase HDAC1 induces cell death in <i>Drosophila</i> epithelial cells through JNK and Hippo signaling. <i>Mechanisms of Development</i> , 2016, 141, 4-13.	1.7	7
875	A potential adjuvant chemotherapeutics, 18 β -glycyrrhetic acid, inhibits renal tubular epithelial cells apoptosis via enhancing BMP-7 epigenetically through targeting HDAC2. <i>Scientific Reports</i> , 2016, 6, 25396.	3.3	20
876	Therapeutic Effect of Histone Deacetylase Inhibitor, Sodium Butyrate, on Allergic Rhinitis <i>In Vivo</i> . <i>DNA and Cell Biology</i> , 2016, 35, 203-208.	1.9	40
877	Targeting cancer using KAT inhibitors to mimic lethal knockouts. <i>Biochemical Society Transactions</i> , 2016, 44, 979-986.	3.4	52
878	Virtual screening and experimental validation of novel histone deacetylase inhibitors. <i>BMC Pharmacology & Toxicology</i> , 2016, 17, 32.	2.4	25
879	Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5183-5196.	3.0	15
880	Epigenetic changes in cancer by Raman imaging, fluorescence imaging, AFM and scanning near-field optical microscopy (SNOM). Acetylation in normal and human cancer breast cells MCF10A, MCF7 and MDA-MB-231. <i>Analyst</i> , 2016, 141, 5646-5658.	3.5	38

#	ARTICLE	IF	CITATIONS
881	Mechanisms of transcription factor acetylation and consequences in hearts. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 2221-2231.	3.8	28
882	Treating Colon Cancer Cells with FK228 Reveals a Link between Histone Lysine Acetylation and Extensive Changes in the Cellular Proteome. <i>Scientific Reports</i> , 2016, 5, 18443.	3.3	12
883	Photothermal therapeutic effect of PEGylated gold nano-semicubes in chemically-induced skin cancer in mice. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2016, 164, 21-29.	3.8	19
884	Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents. <i>AAPS Journal</i> , 2016, 18, 737-745.	4.4	11
885	Efficacy of Combined Epigenetic Therapies. , 2016, , 347-371.		0
886	TET3 Inhibits Type I IFN Production Independent of DNA Demethylation. <i>Cell Reports</i> , 2016, 16, 1096-1105.	6.4	40
887	Sodium Butyrate Upregulates miR-203 Expression to Exert Anti-Proliferation Effect on Colorectal Cancer Cells. <i>Cellular Physiology and Biochemistry</i> , 2016, 39, 1919-1929.	1.6	57
888	Development of a new diagnostic Raman method for monitoring epigenetic modifications in the cancer cells of human breast tissue. <i>Analytical Methods</i> , 2016, 8, 8542-8553.	2.7	39
889	Low Concentration of Sodium Butyrate from Ultrabraid+NaBu suture, Promotes Angiogenesis and Tissue Remodelling in Tendon-bones Injury. <i>Scientific Reports</i> , 2016, 6, 34649.	3.3	13
890	The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair. <i>Nucleic Acids Research</i> , 2016, 44, gkw922.	14.5	94
891	Effects of Chard (<i>Cicheta Vulgaris</i> L. Var. Cicla) on Cardiac Damage in Valproic Acid-Induced Toxicity. <i>Journal of Food Biochemistry</i> , 2016, 40, 132-139.	2.9	6
892	From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. <i>Cell</i> , 2016, 165, 1332-1345.	28.9	3,962
894	Histone deacetylases in monocyte/macrophage development, activation and metabolism: refining HDAC targets for inflammatory and infectious diseases. <i>Clinical and Translational Immunology</i> , 2016, 5, e62.	3.8	96
895	Design and development of sulfonylurea derivatives as zinc metalloenzyme modulators. <i>RSC Advances</i> , 2016, 6, 8923-8929.	3.6	9
896	A modular approach to cyclic tetrapeptides related to histone deacetylase inhibition: synthesis of epi-microsporin A. <i>Tetrahedron Letters</i> , 2016, 57, 739-742.	1.4	6
897	Design, synthesis and biological evaluation of novel hydroxamic acids bearing artemisinin skeleton. <i>Bioorganic Chemistry</i> , 2016, 66, 63-71.	4.1	21
898	Epigenetics and innate immunity: the <i>TollD</i> ™ story. <i>Immunology and Cell Biology</i> , 2016, 94, 631-639.	2.3	22
899	A hybrid of thiazolidinone with the hydroxamate scaffold for developing novel histone deacetylase inhibitors with antitumor activities. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 1727-1735.	2.8	17

#	ARTICLE	IF	CITATIONS
900	Histone deacetylase-mediated silencing of AMWAP expression contributes to cisplatin nephrotoxicity. <i>Kidney International</i> , 2016, 89, 317-326.	5.2	42
901	Butyrate suppresses murine mast cell proliferation and cytokine production through inhibiting histone deacetylase. <i>Journal of Nutritional Biochemistry</i> , 2016, 27, 299-306.	4.2	58
902	Integrated Drug Expression Analysis for leukemia: an integrated in silico and in vivo approach to drug discovery. <i>Pharmacogenomics Journal</i> , 2017, 17, 351-359.	2.0	4
903	A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance. <i>Scientific Reports</i> , 2017, 7, 41615.	3.3	58
904	Novel valproic aminophenol amides with enhanced glial cell viability effect. <i>RSC Advances</i> , 2017, 7, 12391-12399.	3.6	3
905	Synthesis and Biochemical Evaluation of Biotinylated Conjugates of Largazole Analogues: Selective Class I Histone Deacetylase Inhibitors. <i>Israel Journal of Chemistry</i> , 2017, 57, 319-330.	2.3	3
906	Epigenetic Activation of μ -Opioid Receptor Gene via Increased Expression and Function of Mitogen- and Stress-Activated Protein Kinase 1. <i>Molecular Pharmacology</i> , 2017, 91, 357-372.	2.3	9
907	Novel N -hydroxybenzamides incorporating 2-oxindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity. <i>Bioorganic Chemistry</i> , 2017, 71, 160-169.	4.1	24
908	Epigenetics: a link between addiction and social environment. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 2735-2747.	5.4	50
909	Cocktail of chemical compounds robustly promoting cell reprogramming protects liver against acute injury. <i>Protein and Cell</i> , 2017, 8, 273-283.	11.0	15
910	Histone Deacetylase (HDAC) Inhibition Induces I κ B Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells. <i>Journal of Biological Chemistry</i> , 2017, 292, 5043-5054.	3.4	37
911	High-throughput cell mechanical phenotyping for label-free titration assays of cytoskeletal modifications. <i>Cytoskeleton</i> , 2017, 74, 283-296.	2.0	49
912	The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3254-3258.	2.2	16
913	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2 H -chromene derivatives as histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 4123-4132.	3.0	14
914	Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, 560-564.	0.6	8
915	Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review. <i>Gynecologic Oncology Reports</i> , 2017, 20, 81-86.	0.6	44
916	Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy. <i>Molecular Therapy - Oncolytics</i> , 2017, 5, 20-40.	4.4	35
917	Emerging and investigational therapies for neuroblastoma. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 355-368.	0.8	27

#	ARTICLE	IF	CITATIONS
918	Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 510-515.	2.8	30
919	Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. <i>European Journal of Medicinal Chemistry</i> , 2017, 134, 1-12.	5.5	22
920	Effect of small molecules on cell reprogramming. <i>Molecular BioSystems</i> , 2017, 13, 277-313.	2.9	19
921	Site-Specific Acetyl Lysine Antibodies Reveal Differential Regulation of Histone Acetylation upon Kinase Inhibition. <i>Cell Biochemistry and Biophysics</i> , 2017, 75, 119-129.	1.8	3
922	The epigenetic regulation of Dicer and microRNA biogenesis by Panobinostat. <i>Epigenetics</i> , 2017, 12, 105-112.	2.7	12
923	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017, 127, 531-553.	5.5	17
924	Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-Based Histone Deacetylase Inhibitors. <i>ChemMedChem</i> , 2017, 12, 2030-2043.	3.2	9
925	Design, virtual screening, molecular docking and molecular dynamics studies of novel urushiol derivatives as potential HDAC2 selective inhibitors. <i>Gene</i> , 2017, 637, 63-71.	2.2	28
926	Oxygen-Substituted Isocyanates: Blocked (Masked) Isocyanates Enable Controlled Reactivity. <i>Advanced Synthesis and Catalysis</i> , 2017, 359, 4289-4293.	4.3	9
927	Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. <i>Cancer</i> , 2017, 123, 4851-4859.	4.1	45
928	Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazoliny systems as capping groups. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4885-4888.	2.2	13
929	DNA and Histone Methylation in Lung Cancer. <i>Cancer Drug Discovery and Development</i> , 2017, , 403-436.	0.4	3
930	The transformation of the nuclear nanoarchitecture in human field carcinogenesis. <i>Future Science OA</i> , 2017, 3, FSO206.	1.9	8
931	Design, Synthesis, and Biological Evaluation of Tetrahydroisoquinoline-Based Histone Deacetylase 8 Selective Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 824-829.	2.8	29
932	Synthesis, characterization, and evaluation of Cd[L-proline] ₂ , a novel histone deacetylase inhibitor that induces epigenetic modification of histone deacetylase isoforms in A549 cells. <i>Investigational New Drugs</i> , 2017, 35, 691-705.	2.6	9
933	Potent induction of apoptosis by givinostat in BCR-ABL1-positive and BCR-ABL1-negative precursor B-cell acute lymphoblastic leukemia cell lines. <i>Leukemia Research</i> , 2017, 60, 129-134.	0.8	3
934	Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4415-4420.	2.2	22
935	Omics technologies in diagnosis of lung adenocarcinoma. <i>Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry</i> , 2017, 11, 309-340.	0.4	0

#	ARTICLE	IF	CITATIONS
936	Synthesis of <i>N</i> -Oxyureas by Substitution and Cope-Type Hydroamination Reactions Using <i>O</i> -Isocyanate Precursors. <i>Organic Letters</i> , 2017, 19, 6574-6577.	4.6	16
937	Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity. <i>Epigenetics</i> , 2017, 12, 934-944.	2.7	10
938	Paper-based cell culture platform and its emerging biomedical applications. <i>Materials Today</i> , 2017, 20, 32-44.	14.2	105
939	A new ureido-substituted amino acid from the tubers of <i>Gymnadenia conopsea</i> . <i>Chinese Chemical Letters</i> , 2017, 28, 257-259.	9.0	5
940	Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 72, 60-72.	4.8	64
941	Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation. <i>Leukemia</i> , 2017, 31, 669-677.	7.2	17
942	HDAC inhibitors: A new promising drug class in anti-ageing research. <i>Mechanisms of Ageing and Development</i> , 2017, 166, 6-15.	4.6	79
943	<i>Drosophila Epigenetics.</i> , 2017, , 205-229.		3
944	<i>SAMMSON</i> drives the self-renewal of liver tumor initiating cells through EZH2-dependent Wnt/ β -catenin activation. <i>Oncotarget</i> , 2017, 8, 103785-103796.	1.8	16
945	Acetylation and deacetylation in cancer stem-like cells. <i>Oncotarget</i> , 2017, 8, 89315-89325.	1.8	62
946	The Molecular Basis of Toxins™ Interactions with Intracellular Signaling via Discrete Portals. <i>Toxins</i> , 2017, 9, 107.	3.4	29
947	Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits <i>Ex Vivo</i> Lipopolysaccharide-Induced Inflammatory Responses. <i>MSphere</i> , 2018, 3, .	2.9	17
948	The discovery of novel HDAC3 inhibitors via virtual screening and <i>in vitro</i> bioassay. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018, 33, 525-535.	5.2	15
950	Synthesis and Evaluation of 2-[18F]Fluoroethyltriazolesuberohydroxamine Acid for Histone Deacetylase in a Tumor Model as a Positron Emission Tomography Radiotracer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2018, 33, 52-59.	1.0	5
951	Total synthesis of the natural HDAC inhibitor Cyl-1. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 3464-3472.	2.8	12
952	A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target. <i>Brain</i> , 2018, 141, 744-761.	7.6	54
953	New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death. <i>Scientific Reports</i> , 2018, 8, 1400.	3.3	18
954	Cooperativity of HOXA5 and STAT3 Is Critical for HDAC8 Inhibition-Mediated Transcriptional Activation of PD-L1 in Human Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2018, 138, 922-932.	0.7	26

#	ARTICLE	IF	CITATIONS
955	Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma. <i>Experimental Cell Research</i> , 2018, 363, 196-207.	2.6	20
956	Current and future technological advances in transdermal gene delivery. <i>Advanced Drug Delivery Reviews</i> , 2018, 127, 85-105.	13.7	58
957	Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs. <i>Journal of Drug Targeting</i> , 2018, 26, 448-457.	4.4	25
958	Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. <i>MedChemComm</i> , 2018, 9, 344-352.	3.4	14
959	HDAC Inhibitors: Novel Immunosuppressants for Alloë•and Xenoë•Transplantation. <i>ChemistrySelect</i> , 2018, 3, 176-187.	1.5	5
960	A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer. <i>European Journal of Pharmacology</i> , 2018, 828, 67-79.	3.5	26
961	Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?. <i>European Respiratory Review</i> , 2018, 27, 170098.	7.1	21
962	Microbiotaë•Host Transgenomic Metabolism, Bioactive Molecules from the Inside. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 47-61.	6.4	91
963	Whole cereal grains and potential health effects: Involvement of the gut microbiota. <i>Food Research International</i> , 2018, 103, 84-102.	6.2	136
964	Natural Agents-Mediated Targeting of Histone Deacetylases. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 31-44.	2.3	5
965	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 320-333.	5.5	36
966	Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay. <i>Journal of Biomolecular Structure and Dynamics</i> , 2018, 36, 3231-3245.	3.5	29
967	Role of MeCP2 in neurological disorders: current status and future perspectives. <i>Epigenomics</i> , 2018, 10, 5-8.	2.1	15
968	Synthesis of the molecular hybrid inspired by Largazole and Psammaplin A. <i>Tetrahedron</i> , 2018, 74, 549-555.	1.9	9
969	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 792-805.	5.5	20
970	HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL. <i>Biochemical Pharmacology</i> , 2018, 147, 30-37.	4.4	43
971	Differentiation therapy revisited. <i>Nature Reviews Cancer</i> , 2018, 18, 117-127.	28.4	320
972	Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 25-36.	3.0	23

#	ARTICLE	IF	CITATIONS
973	The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 1790-1806.	5.5	33
975	Histone deacetylase inhibitors alter the expression of molecular markers in breast cancer cells via microRNAs. <i>International Journal of Molecular Medicine</i> , 2018, 42, 435-442.	4.0	6
976	6- and 8-Prenylningenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells. <i>Cellular Physiology and Biochemistry</i> , 2018, 51, 543-556.	1.6	25
977	Leptin Receptor Antagonists' Action on HDAC Expression Eliminating the Negative Effects of Leptin in Ovarian Cancer. <i>Cancer Genomics and Proteomics</i> , 2018, 15, 329-336.	2.0	7
978	Identification of Deregulated Signaling Pathways in Jurkat Cells in Response to a Novel Acylspermidine Analogue-N4-Erucyl Spermidine. <i>Epigenetics Insights</i> , 2018, 11, 251686571881454.	2.0	12
979	Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule. <i>Cell Death Discovery</i> , 2018, 4, 41.	4.7	30
980	Cancer Chemoradiotherapy Duo: Nano-Enabled Targeting of DNA Lesion Formation and DNA Damage Response. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 35734-35744.	8.0	30
981	Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling. <i>Theranostics</i> , 2018, 8, 4995-5011.	10.0	48
982	Development of the first small molecule histone deacetylase 6 (HDAC6) degraders. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2493-2497.	2.2	135
983	Renal Toxicology/Nephrotoxicity of Cisplatin and Other Chemotherapeutic Agents. , 2018, , 452-486.		1
984	Multiple functions of p27 in cell cycle, apoptosis, epigenetic modification and transcriptional regulation for the control of cell growth: A double-edged sword protein. <i>DNA Repair</i> , 2018, 69, 63-72.	2.8	140
985	Gut microbiota promotes production of aromatic metabolites through degradation of barley leaf fiber. <i>Journal of Nutritional Biochemistry</i> , 2018, 58, 49-58.	4.2	21
986	Radiosensitivity enhancement of human thyroid carcinoma cells by the inhibitors of histone deacetylase sodium butyrate and valproic acid. <i>Molecular and Cellular Endocrinology</i> , 2018, 478, 141-150.	3.2	21
987	Post-Translational Modifications in NETosis and NETs-Mediated Diseases. <i>Biomolecules</i> , 2019, 9, 369.	4.0	67
988	Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. <i>Blood Advances</i> , 2019, 3, 508-518.	5.2	62
989	DNA G-Quadruplexes (G4s) Modulate Epigenetic (Re)Programming and Chromatin Remodeling. <i>BioEssays</i> , 2019, 41, e1900091.	2.5	23
990	Analysis of Human Colon by Raman Spectroscopy and Imaging-Elucidation of Biochemical Changes in Carcinogenesis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3398.	4.1	36
991	Development of Multifunctional Histone Deacetylase 6 Degradors with Potent Antimyeloma Activity. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7042-7057.	6.4	121

#	ARTICLE	IF	CITATIONS
992	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2499-2511.	2.4	14
993	Chemoresistance in the Human Triple-Negative Breast Cancer Cell Line MDA-MB-231 Induced by Doxorubicin Gradient Is Associated with Epigenetic Alterations in Histone Deacetylase. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	1.3	44
994	Trichostatin A, a Histone Deacetylase Inhibitor, Alleviates Eosinophilic Meningitis Induced by <i>Angiostrongylus cantonensis</i> Infection in Mice. <i>Frontiers in Microbiology</i> , 2019, 10, 2280.	3.5	7
995	Divergent Access to Histone Deacetylase Inhibitory Cyclopeptides via a Late-Stage Cyclopropane Ring Cleavage Strategy. <i>Short Synthesis of Chlamydocin</i> . <i>Organic Letters</i> , 2019, 21, 8473-8478.	4.6	16
996	HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer. <i>British Journal of Cancer</i> , 2019, 121, 1039-1049.	6.4	34
997	Comprehensive Exploration to Identify Predictive DNA Markers of ^{177}Lu -Np63/SOX2 in Drug Resistance in Human Esophageal Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 4814-4825.	1.5	2
998	Potential of epigenetic events in human thyroid cancer. <i>Cancer Genetics</i> , 2019, 239, 13-21.	0.4	17
999	Postbiotics and Their Potential Applications in Early Life Nutrition and Beyond. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4673.	4.1	310
1000	A fluorine scan on the Zn ²⁺ -binding thiolate side chain of HDAC inhibitor largazole: Synthesis, biological evaluation, and molecular modeling. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111672.	5.5	7
1001	Histone Deacetylase Inhibitors in Cancer Prevention and Therapy. , 2019, , 75-105.		3
1002	Enzyme-instructed self-assembly of a novel histone deacetylase inhibitor with enhanced selectivity and anticancer efficiency. <i>Biomaterials Science</i> , 2019, 7, 1477-1485.	5.4	37
1003	Changes in the gut microbiome and fermentation products concurrent with enhanced longevity in acarbose-treated mice. <i>BMC Microbiology</i> , 2019, 19, 130.	3.3	218
1004	Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy. <i>Cancers</i> , 2019, 11, 850.	3.7	31
1005	Synthesis and Preliminary Biological Evaluation of Two Fluoroolefin Analogs of Largazole Inspired by the Structural Similarity of the Side Chain Unit in Psammaphin A. <i>Marine Drugs</i> , 2019, 17, 333.	4.6	7
1006	Histone deacetylase activity mediates thermal plasticity in zebrafish (<i>Danio rerio</i>). <i>Scientific Reports</i> , 2019, 9, 8216.	3.3	14
1007	Embryonic and Induced Pluripotent Stem Cells and Their Differentiation in the Cardiomyocyte Direction in the Presence of Dimethyl Sulfoxide. <i>Cytology and Genetics</i> , 2019, 53, 34-41.	0.5	2
1008	A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. <i>British Journal of Cancer</i> , 2019, 120, 1105-1112.	6.4	22
1009	Roles of volume-regulatory anion channels, VSOR and Maxi-Cl, in apoptosis, cisplatin resistance, necrosis, ischemic cell death, stroke and myocardial infarction. <i>Current Topics in Membranes</i> , 2019, 83, 205-283.	0.9	34

#	ARTICLE	IF	CITATIONS
1010	Quantifying Tip60 (Kat5) stratifies breast cancer. <i>Scientific Reports</i> , 2019, 9, 3819.	3.3	17
1011	Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1291.	4.1	47
1012	Stable isotope labeling combined with liquid chromatography-tandem mass spectrometry for comprehensive analysis of short-chain fatty acids. <i>Analytica Chimica Acta</i> , 2019, 1070, 51-59.	5.4	43
1013	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 173, 185-202.	5.5	16
1014	Momordica charantia juice with Lactobacillus plantarum fermentation: Chemical composition, antioxidant properties and aroma profile. <i>Food Bioscience</i> , 2019, 29, 62-72.	4.4	62
1015	Comprehensive Structure-Activity Relationship Studies of Macrocyclic Natural Products Enabled by Their Total Syntheses. <i>Chemical Reviews</i> , 2019, 119, 10002-10031.	47.7	70
1016	Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models. <i>International Journal of Cancer</i> , 2019, 145, 735-747.	5.1	60
1017	Trichostatin A modulates cellular metabolism in renal cell carcinoma to enhance sunitinib sensitivity. <i>European Journal of Pharmacology</i> , 2019, 847, 143-157.	3.5	13
1018	Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 84.	8.6	45
1019	How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2467-2480.	3.5	86
1020	Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 2081-2094.	4.2	28
1021	Biology, pathophysiology, and epidemiology of pancreatic cancer. , 2019, , 1-50.		4
1022	Effects of dietary intake of potatoes on body weight gain, satiety-related hormones, and gut microbiota in healthy rats. <i>RSC Advances</i> , 2019, 9, 33290-33301.	3.6	7
1023	Histone deacetylase inhibitors reactivate silenced transgene in vivo. <i>Gene Therapy</i> , 2019, 26, 75-85.	4.5	5
1024	Current trends in protein acetylation analysis. <i>Expert Review of Proteomics</i> , 2019, 16, 139-159.	3.0	51
1025	Highly fluorescent and HDAC6 selective scriptaid analogues. <i>European Journal of Medicinal Chemistry</i> , 2019, 162, 321-333.	5.5	21
1026	Downregulation of HDAC2 and HDAC3 via oleuropein as a potent prevention and therapeutic agent in MCF7 breast cancer cells. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 9172-9180.	2.6	35
1027	Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells. <i>Phytomedicine</i> , 2019, 56, 94-102.	5.3	27

#	ARTICLE	IF	CITATIONS
1028	The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma. <i>Cancer Biology and Therapy</i> , 2019, 20, 272-283.	3.4	11
1029	In vitro digestibility and prebiotic potential of a novel polysaccharide from <i>Rosa roxburghii</i> Tratt fruit. <i>Journal of Functional Foods</i> , 2019, 52, 408-417.	3.4	64
1030	Molecular modeling study of uracil-based hydroxamic acids-containing histone deacetylase inhibitors. <i>Arabian Journal of Chemistry</i> , 2019, 12, 2206-2215.	4.9	0
1031	Bortezomib and Vorinostat Therapy as Maintenance Therapy after Autologous Transplant for Multiple Myeloma. <i>Acta Haematologica</i> , 2020, 143, 146-154.	1.4	3
1032	Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2020, 61, 309-317.	1.3	22
1033	Rapid Detection of Short-Chain Fatty Acids in Biological Samples. <i>Chromatographia</i> , 2020, 83, 305-310.	1.3	8
1034	Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines. <i>Bioorganic Chemistry</i> , 2020, 95, 103522.	4.1	31
1035	Targeting miRNAs by histone deacetylase inhibitors (HDACi): Rationalizing epigenetics-based therapies for breast cancer. , 2020, 206, 107437.		24
1036	Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy. <i>Biochemical and Biophysical Research Communications</i> , 2020, 522, 604-611.	2.1	32
1037	The application of histone deacetylases inhibitors in glioblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 138.	8.6	59
1038	The Versatility of Sirtuin-1 in Endocrinology and Immunology. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 589016.	3.7	20
1039	Diet as a Modulator of Intestinal Microbiota in Rheumatoid Arthritis. <i>Nutrients</i> , 2020, 12, 3504.	4.1	38
1040	Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 560487.	2.8	44
1041	State-of-the-Art of the Nutritional Alternatives to the Use of Antibiotics in Humans and Monogastric Animals. <i>Animals</i> , 2020, 10, 2199.	2.3	18
1042	The Effect of Sodium Butyrate on Adventitious Shoot Formation Varies among the Plant Species and the Explant Types. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8451.	4.1	7
1043	Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer. <i>European Journal of Medicinal Chemistry</i> , 2020, 205, 112648.	5.5	30
1044	Taming the Sentinels: Microbiome-Derived Metabolites and Polarization of T Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7740.	4.1	12
1045	Liver-Specific Knockdown of Class IIa HDACs Has Limited Efficacy on Glucose Metabolism but Entails Severe Organ Side Effects in Mice. <i>Frontiers in Endocrinology</i> , 2020, 11, 598.	3.5	7

#	ARTICLE	IF	CITATIONS
1046	A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 14609-14614.	13.8	22
1047	The homogenous polysaccharide SY01-23 purified from leaf of <i>Morus alba</i> L. has bioactivity on human gut <i>Bacteroides ovatus</i> and <i>Bacteroides cellulosilyticus</i> . <i>International Journal of Biological Macromolecules</i> , 2020, 158, 698-707.	7.5	12
1048	Synthesis and Biological Evaluation of a Depsipeptidic Histone Deacetylase Inhibitor via a Generalizable Approach Using an Optimized Latent Thioester Solid-Phase Linker. <i>Journal of Organic Chemistry</i> , 2020, 85, 8253-8260.	3.2	4
1049	Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 425.	3.7	28
1050	Wine pomace product modulates oxidative stress and microbiota in obesity high-fat diet-fed rats. <i>Journal of Functional Foods</i> , 2020, 68, 103903.	3.4	15
1051	Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 575-581.	2.8	79
1052	Role of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents. <i>Molecules</i> , 2020, 25, 1615.	3.8	70
1053	Nuclear actin in cancer biology. <i>International Review of Cell and Molecular Biology</i> , 2020, 355, 53-66.	3.2	4
1054	Unexpected Enhancement of HDACs Inhibition by MeS Substitution at C-2 Position of Fluoro Largazole. <i>Marine Drugs</i> , 2020, 18, 344.	4.6	4
1055	Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer. <i>Cancer Research</i> , 2020, 80, 3507-3518.	0.9	28
1056	Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials. <i>Radiotherapy and Oncology</i> , 2020, 150, 225-235.	0.6	12
1057	Gut Microbiota of Wild and Captive Alpine Musk Deer (<i>Moschus chrysogaster</i>). <i>Frontiers in Microbiology</i> , 2019, 10, 3156.	3.5	42
1058	<p>Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 497-508.	4.3	35
1059	Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures. <i>Nanomaterials</i> , 2020, 10, 158.	4.1	17
1060	Functionalized Graphene Oxide Thin Films for Anti-tumor Drug Delivery to Melanoma Cells. <i>Frontiers in Chemistry</i> , 2020, 8, 184.	3.6	22
1061	Synthesis and biological evaluation of thiophene-based hydroxamate derivatives as HDACis with antitumor activities. <i>Future Medicinal Chemistry</i> , 2020, 12, 655-672.	2.3	14
1062	HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. <i>Blood</i> , 2020, 135, 191-207.	1.4	40
1063	Dietary fiber metabolites regulate innate lymphoid cell responses. <i>Mucosal Immunology</i> , 2021, 14, 317-330.	6.0	76

#	ARTICLE	IF	CITATIONS
1064	HDAC3iâ€Finder: A Machine Learningâ€based Computational Tool to Screen for HDAC3 Inhibitors. <i>Molecular Informatics</i> , 2021, 40, e2000105.	2.5	16
1065	Modification of Proteins by Metabolites in Immunity. <i>Immunity</i> , 2021, 54, 19-31.	14.3	86
1066	Sirtuins as regulators and the regulated molecules of exosomes. , 2021, , 91-101.		0
1067	Integration of constraint-based modeling with fecal metabolomics reveals large deleterious effects of <i>Fusobacterium</i> spp. on community butyrate production. <i>Gut Microbes</i> , 2021, 13, 1-23.	9.8	22
1068	Trichostatin A ameliorates Alzheimerâ€™s disease-related pathology and cognitive deficits by increasing albumin expression and A β clearance in APP/PS1 mice. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 7.	6.2	27
1069	Fluorescent Nanohybrids from ZnS/CdSe Quantum Dots Functionalized with Triantennary, <i>N</i> -Hydroxy- <i>p</i> -(4-arylbutanamido)benzamide/Gallamide Dendrons That Act as Inhibitors of Histone Deacetylase for Lung Cancer. <i>ACS Applied Bio Materials</i> , 2021, 4, 2475-2489.	4.6	3
1070	Molecular dynamics-guided receptor-dependent 4D-QSAR studies of HDACs inhibitors. <i>Molecular Diversity</i> , 2022, 26, 757-768.	3.9	6
1071	An efficient system for intestinal on-site butyrate production using novel microbiome-derived esterases. <i>Journal of Biological Engineering</i> , 2021, 15, 9.	4.7	1
1072	Multivalent display of chemical signals on selfâ€assembled peptide scaffolds. <i>Peptide Science</i> , 2021, 113, e24224.	1.8	8
1073	In Vivo Evaluation of the Combined Anticancer Effects of Cisplatin and SAHA in Nonsmall Cell Lung Carcinoma Using [18F]FAHA and [18F]FDG PET/CT Imaging. <i>Molecular Imaging</i> , 2021, 2021, 1-11.	1.4	3
1074	Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 665-673.	4.1	2
1075	Phosphate, Microbiota and CKD. <i>Nutrients</i> , 2021, 13, 1273.	4.1	18
1076	Î²-Cyclodextrin-poly (Î²-Amino Ester) Nanoparticles Are a Generalizable Strategy for High Loading and Sustained Release of HDAC Inhibitors. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 20960-20973.	8.0	15
1077	New side chain design for pH-responsive block copolymers for drug delivery. <i>Colloids and Surfaces B: Biointerfaces</i> , 2021, 200, 111563.	5.0	10
1078	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition. <i>European Journal of Medicinal Chemistry</i> , 2021, 215, 113169.	5.5	23
1079	Current Therapies in Nephrotic Syndrome: HDAC inhibitors, an Emerging Therapy for Kidney Diseases. <i>Current Research in Biotechnology</i> , 2021, 3, 182-194.	3.7	3
1080	Latency Reversing Agents: Kick and Kill of HTLV-1?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5545.	4.1	10
1081	The fecal microbiota of patients with pancreatic ductal adenocarcinoma and autoimmune pancreatitis characterized by metagenomic sequencing. <i>Journal of Translational Medicine</i> , 2021, 19, 215.	4.4	39

#	ARTICLE	IF	CITATIONS
1082	Histone deacetylaseâ€²: A potential regulator and therapeutic target in liver disease (Review). International Journal of Molecular Medicine, 2021, 48, .	4.0	11
1083	8a, a New Acridine Antiproliferative and Pro-Apoptotic Agent Targeting HDAC1/DNMT1. International Journal of Molecular Sciences, 2021, 22, 5516.	4.1	3
1084	An Assessment on Ethanol-Blended Gasoline/Diesel Fuels on Cancer Risk and Mortality. International Journal of Environmental Research and Public Health, 2021, 18, 6930.	2.6	7
1085	Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives. Cancers, 2021, 13, 2761.	3.7	19
1086	Mini review â€œ The role of Glucocerebrosidase and Progranulin as possible targets in the treatment of Parkinson's disease. Revue Neurologique, 2021, 177, 1082-1089.	1.5	4
1087	Oroxilin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression. Acta Pharmacologica Sinica, 2022, 43, 724-734.	6.1	9
1088	KDEL2 promotes breast cancer proliferation via HDAC3â€mediated cell cycle progression. Cancer Communications, 2021, 41, 904-920.	9.2	23
1089	Molecular Markers that Matter in Salivary Malignancy. Otolaryngologic Clinics of North America, 2021, 54, 613-627.	1.1	2
1090	The role of the intestinal microbiota in eating disorders â€œ bulimia nervosa and binge eating disorder. Psychiatry Research, 2021, 300, 113923.	3.3	9
1091	Insights Into the Function and Clinical Application of HDAC5 in Cancer Management. Frontiers in Oncology, 2021, 11, 661620.	2.8	13
1092	Emerging role of nutritional short-chain fatty acids (SCFAs) against cancer via modulation of hematopoiesis. Critical Reviews in Food Science and Nutrition, 2023, 63, 827-844.	10.3	16
1093	Synthesis and antibacterial study of cell-penetrating peptide conjugated trifluoroacetyl and thioacetyl lysine modified peptides. European Journal of Medicinal Chemistry, 2021, 219, 113447.	5.5	7
1094	Epigenetic modulators for brain cancer stem cells: Implications for anticancer treatment. World Journal of Stem Cells, 2021, 13, 670-684.	2.8	7
1095	Vorinostat ameliorates ILâ€1â€±â€induced reduction of type II collagen by inhibiting the expression of ELF3 in chondrocytes. Journal of Biochemical and Molecular Toxicology, 2021, 35, e22844.	3.0	4
1096	Epigenetic â€œDriversâ€of Cancer. Journal of Molecular Biology, 2021, 433, 167094.	4.2	12
1097	Conversion of dietary inositol into propionate and acetate by commensal Anaerostipes associates with host health. Nature Communications, 2021, 12, 4798.	12.8	76
1098	Novel Conjugated Quinazolinone-Based Hydroxamic Acids: Design, Synthesis and Biological Evaluation. Medicinal Chemistry, 2021, 17, 732-749.	1.5	6
1099	A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 6222-6234.	7.0	17

#	ARTICLE	IF	CITATIONS
1100	Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors. <i>Bioorganic Chemistry</i> , 2021, 114, 105050.	4.1	14
1101	Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 702360.	3.5	15
1102	Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma. , 2021, 62, 16.		4
1103	Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 112024.	5.6	41
1104	Ionic liquid-based cationic vesicles: A de novo system to judiciously improve the solubility, stability and antimicrobial activity of curcumin. <i>Journal of Molecular Liquids</i> , 2021, 341, 117396.	4.9	24
1105	Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 592868.	3.7	20
1106	A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor. <i>Angewandte Chemie</i> , 2020, 132, 14717-14722.	2.0	4
1107	Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer. <i>Cancer Medicine</i> , 2021, 10, 709-717.	2.8	14
1108	Targeted histone deacetylase inhibition for cancer prevention and therapy. , 2005, 63, 147-191.		7
1109	Histone Deacetylases. <i>Advances in Experimental Medicine and Biology</i> , 2008, 625, 81-86.	1.6	12
1110	Combination Therapy for Cancer: Phototherapy and HDAC Inhibition. , 2014, , 445-470.		1
1111	Epigenetic Inhibitors. <i>Methods in Molecular Biology</i> , 2015, 1238, 469-485.	0.9	13
1112	Epigenetic Therapy for Colorectal Cancer. <i>Methods in Molecular Biology</i> , 2015, 1238, 771-782.	0.9	13
1113	Emerging Molecular Therapies. , 2004, , 569-606.		3
1114	Targeting Histone Deacetylase as a Strategy for Cancer Prevention. , 2004, , 659-678.		3
1115	Current Epigenetic Therapy for T-Cell Lymphoma. , 2013, , 279-296.		2
1116	The Chemistry of Hydroxamic Acids. , 2013, , 1-17.		5
1117	Epigenetic Regulation of Normal Hematopoietic Development. , 2014, , 67-87.		1

#	ARTICLE	IF	CITATIONS
1118	Chemoprevention of Prostate Cancer with Cruciferous Vegetables: Role of Epigenetics. , 2012, , 49-81.		2
1119	Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis. <i>Modern Rheumatology</i> , 2010, 20, 11-17.	1.8	58
1120	Novel Therapeutics Targeting Epigenetics. , 2017, , 297-328.		1
1121	Design of polyamine-based therapeutic agents: new targets and new directions. <i>Essays in Biochemistry</i> , 2009, 46, 77-94.	4.7	18
1122	KRASG12C inhibitor: combing for combination. <i>Biochemical Society Transactions</i> , 2020, 48, 2691-2701.	3.4	10
1123	Effects of dietary tributyrin on growth performance, body composition, serum biochemical indexes and lipid metabolism-related genes expression of juvenile large yellow croaker (<i>Larimichthys</i>) Tj ETQq1 1 0.784314 rgBT10 Overlook		
1124	Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. <i>Histopathology</i> , 2008, 53, ???-???	2.9	49
1125	Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. <i>Journal of Clinical Investigation</i> , 2003, 111, 539-552.	8.2	345
1127	Epigenome-Derived Drugs: Recent Advances and Future Perspectives. <i>Drug News and Perspectives</i> , 2007, 20, 627.	1.5	6
1128	Resveratrol, by Modulating RNA Processing Factor Levels, Can Influence the Alternative Splicing of Pre-mRNAs. <i>PLoS ONE</i> , 2011, 6, e28926.	2.5	34
1129	TSA Suppresses miR-106b-93-25 Cluster Expression through Downregulation of MYC and Inhibits Proliferation and Induces Apoptosis in Human EMC. <i>PLoS ONE</i> , 2012, 7, e45133.	2.5	50
1130	PSG Gene Expression Is Up-Regulated by Lysine Acetylation Involving Histone and Nonhistone Proteins. <i>PLoS ONE</i> , 2013, 8, e55992.	2.5	13
1131	Unique Anti-Glioblastoma Activities of Hypericin Are at the Crossroad of Biochemical and Epigenetic Events and Culminate in Tumor Cell Differentiation. <i>PLoS ONE</i> , 2013, 8, e73625.	2.5	20
1132	Trichostatin A Targets the Mitochondrial Respiratory Chain, Increasing Mitochondrial Reactive Oxygen Species Production to Trigger Apoptosis in Human Breast Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e91610.	2.5	36
1133	Quantitative Profiling of Lysine Acetylation Reveals Dynamic Crosstalk between Receptor Tyrosine Kinases and Lysine Acetylation. <i>PLoS ONE</i> , 2015, 10, e0126242.	2.5	14
1134	The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer. <i>PLoS ONE</i> , 2016, 11, e0158208.	2.5	28
1135	Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation. <i>PLoS ONE</i> , 2016, 11, e0164811.	2.5	17
1136	Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates. <i>PLoS ONE</i> , 2017, 12, e0188859.	2.5	10

#	ARTICLE	IF	CITATIONS
1137	Novel anticancer agents in clinical and preclinical trials. El Mednifico Journal, 2014, 2, 38.	0.1	1
1139	Delphinidin induces apoptosis via cleaved HDAC3-mediated p53 acetylation and oligomerization in prostate cancer cells. Oncotarget, 2016, 7, 56767-56780.	1.8	54
1140	Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation <i>via</i> UGT1A1. Oncotarget, 2017, 8, 41572-41581.	1.8	9
1141	The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis. Oncotarget, 2017, 8, 48737-48754.	1.8	48
1142	HDAC/IKK inhibition therapies in solid tumors. Oncotarget, 2017, 8, 34030-34031.	1.8	5
1143	Epigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells. Oncotarget, 2017, 8, 70798-70810.	1.8	18
1144	Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway. Oncotarget, 2017, 8, 87307-87316.	1.8	14
1145	HDAC1 controls <i>CIP2A</i> transcription in human colorectal cancer cells. Oncotarget, 2016, 7, 25862-25871.	1.8	13
1146	LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition. Oncotarget, 2016, 7, 33484-33497.	1.8	30
1147	Histone deacetylases in vascular permeability and remodeling associated with acute lung injury. Vessel Plus, 2018, 2, 15.	0.4	9
1148	Recent Perspectives of Anticancer Histone Deacetylase Inhibitors. Journal of Advanced Biomedical and Pharmaceutical Sciences, 2019, .	0.4	3
1149	Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update. Current Medicinal Chemistry, 2020, 26, 7212-7280.	2.4	16
1150	Nuclear Architecture and Gene Expression in the Quest for Novel Therapeutics. Current Pharmaceutical Design, 2004, 10, 2851-2860.	1.9	11
1151	The Use of Conformational Restriction in Medicinal Chemistry. Current Topics in Medicinal Chemistry, 2019, 19, 1712-1733.	2.1	26
1152	5-Aryl-1,3,4-Thiadiazole-Based Hydroxamic Acids as Histone Deacetylase Inhibitors and Antitumor Agents: Synthesis, Bioevaluation and Docking Study. Medicinal Chemistry, 2015, 11, 296-304.	1.5	6
1153	Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019). Recent Patents on Anti-Cancer Drug Discovery, 2020, 15, 32-48.	1.6	21
1154	Novel Histone Deacetylase Inhibitors for the Treatment of Pediatric Brain Tumors. Central Nervous System Agents in Medicinal Chemistry, 2015, 14, 90-95.	1.1	1
1155	Gas Chromatography Detection Protocol of Short-chain Fatty Acids in Mice Feces. Bio-protocol, 2020, 10, e3672.	0.4	7

#	ARTICLE	IF	CITATIONS
1156	Genistein and Trichostatin A Induction of Estrogen Receptor Alpha Gene Expression, Apoptosis and Cell Growth Inhibition in Hepatocellular Carcinoma HepG 2 Cells. Asian Pacific Journal of Cancer Prevention, 2017, 18, 3445-3450.	1.2	20
1157	In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2507-2510.	1.2	19
1158	The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment. Future Oncology, 2020, 16, 2457-2469.	2.4	15
1160	Acetylation in the regulation of metalloproteinase and tissue inhibitor of metalloproteinases gene expression. Frontiers in Bioscience - Landmark, 2007, 12, 528.	3.0	21
1162	Marine-Derived Secondary Metabolites as Promising Epigenetic Bio-Compounds for Anticancer Therapy. Marine Drugs, 2021, 19, 15.	4.6	12
1163	Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World Journal of Gastroenterology, 2007, 13, 4458.	3.3	55
1164	Effects of SAHA on proliferation and apoptosis of hepatocellular carcinoma cells and hepatitis B virus replication. World Journal of Gastroenterology, 2013, 19, 5159.	3.3	24
1165	Radiosensitizing Efficacy of Diosmin- Hesperidin Complex Against Ehrlich Solid Carcinoma in Mice, A Potential Role of Histone Deacetylase and Pro-angiogenic Chaperones Targeting. International Journal of Cancer Research, 2017, 13, 59-70.	0.2	2
1166	Sodium butyrate induces apoptosis of human colon cancer cells by modulating ERK and sphingosine kinase 2. Biomedical and Environmental Sciences, 2014, 27, 197-203.	0.2	21
1167	Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer. Biomolecules and Therapeutics, 2012, 20, 313-319.	2.4	5
1168	Trichostatin A Protects Liver against Septic Injury through Inhibiting Toll-Like Receptor Signaling. Biomolecules and Therapeutics, 2016, 24, 387-394.	2.4	23
1169	Molecular Basis of Aging and Breast Cancer. Journal of Cancer Science & Therapy, 2013, 05, .	1.7	1
1170	Retinoblastoma as an Epigenetic Disease: A Proposal. Journal of Cancer Therapy, 2011, 02, 362-371.	0.4	4
1171	Histone acetylation and its role in embryonic stem cell differentiation. World Journal of Stem Cells, 2010, 2, 121.	2.8	20
1172	Synthesis of Novel N-(2-Hydroxyphenyl)arylsulfonamides as Selective HDAC Inhibitory and Cytotoxic Agents. Bulletin of the Korean Chemical Society, 2013, 34, 1487-1493.	1.9	3
1173	Combination therapies improve the anticancer activities of retinoids in neuroblastoma. World Journal of Clinical Oncology, 2015, 6, 212.	2.3	16
1174	Knockdown of SMYD3 by RNA interference inhibits cervical carcinoma cell growth and invasion in vitro. BMB Reports, 2008, 41, 294-299.	2.4	54
1175	Role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy. BMB Reports, 2015, 48, 131-138.	2.4	26

#	ARTICLE	IF	CITATIONS
1176	Assessment for the identification of better HDAC inhibitor class through binding energy calculations and descriptor analysis. <i>Bioinformation</i> , 2008, 3, 218-222.	0.5	13
1177	Selection of an improved HDAC8 inhibitor through structure-based drug design. <i>Bioinformation</i> , 2011, 7, 134-141.	0.5	18
1178	Molecular docking and ADMET analysis of hydroxamic acids as HDAC2 inhibitors. <i>Bioinformation</i> , 2019, 15, 380-387.	0.5	10
1179	HDAC inhibitors: applications in oncology and beyond. <i>HOAJ Biology</i> , 2013, 2, 1.	1.0	11
1180	Pharmacological Analysis of Vorinostat Analogues as Potential Anti-tumor Agents Targeting Human Histone Deacetylases: an Epigenetic Treatment Stratagem for Cancers. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016, 17, 1571-1576.	1.2	18
1181	Antioxidant, Anticancer and Antimicrobial, Effects of <i>Rubia cordifolia</i> Aqueous Root Extract. <i>Journal of Advances in Biology & Biotechnology</i> , 2016, 5, 1-8.	0.2	4
1182	Non-bonding energy directed designing of HDAC2 inhibitors through molecular dynamics simulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 13432-13455.	3.5	4
1183	Epigenetic targeting for lung cancer treatment via CRISPR/Cas9 technology. <i>Advances in Cancer Biology Metastasis</i> , 2021, 3, 100012.	2.0	3
1184	Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities. <i>Bioorganic Chemistry</i> , 2021, 117, 105407.	4.1	6
1185	Clinical and Pathological Characteristics of Huntington Disease. , 2005, , 299-307.		0
1187	The Chemotherapy of Cancer. , 2005, , 411-521.		1
1188	Transcriptional Activation and Repression of Cell Cycle Regulatory Molecules by Trichostatin A. <i>Journal of Life Science</i> , 2005, 15, 994-1004.	0.2	0
1189	Acetylation and Histone Deacetylase Inhibitors in Cancer. <i>Analytical Cellular Pathology</i> , 2006, 28, 191-222.	1.4	13
1190	Reelin Downregulation as a Prospective Treatment Target for GABAergic Dysfunction in Schizophrenia. , 2008, , 341-363.		1
1191	BIOLOGY AND EPIDEMIOLOGY OF LUNG CANCER. , 2008, , 708-728.		2
1192	Overview of Cancer Molecular Radiobiology. <i>Cancer Treatment and Research</i> , 2008, , 115-131.	0.5	2
1194	The Combination Effect of Sodium Butyrate, 5-aza-2'-deoxycytidine on the Tumor Suppressive Activity in RKO Colorectal Cancer and MCF-7 Breast Cancer Cell Lines. [Chapchi] <i>Journal Taehan Oekwa Hakhoe</i> , 2009, 76, 279.	1.1	0
1195	Aktuelles zu kutanen Lymphomen. <i>Fortschritte Der Praktischen Dermatologie Und Venerologie</i> , 2009, , 86-94.	0.0	0

#	ARTICLE	IF	CITATIONS
1196	G1 Phase Cyclins in Cancer Development and Progression. , 2010, , 123-153.		0
1197	Reprogramming of Somatic Cells: Generation of iPS from Adult Cells. Reproductive Medicine and Assisted Reproductive Techniques Series, 2009, , 208-225.	0.1	0
1198	Reprogramming of Somatic Cells: Generation of iPS from Adult Cells. Reproductive Medicine and Assisted Reproductive Techniques Series, 2009, , 208-225.	0.1	0
1199	Optimization and Comparison of Different DNA Methyl Transferase and Histone Deacetylase Inhibitors for Enhancing Transient Protein Expression. , 2010, , 261-264.		0
1200	Use of Polyamine Derivatives as Selective Histone Deacetylase Inhibitors. Methods in Molecular Biology, 2011, 720, 475-491.	0.9	0
1201	Novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction in oral squamous cell carcinoma. Journal of Biophysical Chemistry, 2011, 02, 215-221.	0.5	1
1202	Symmetrical- and Unsymmetrical Terminally Alkylated Polyamines. RSC Drug Discovery Series, 2011, , 104-134.	0.3	1
1204	A Histone Deacetylase Inhibitor, FR276457, Altered Characteristics of Infiltrating Cells into Allograft in a Rat Cardiac Transplant Model. Journal of Transplantation Technologies & Research, 2012, 02, .	0.1	0
1205	Cancer and the Nervous System. , 2012, , 1141-1157.		0
1206	On the Identification of Drugs Modulating Epigenetic Mechanisms in Depression. , 2013, , 145-164.		0
1207	Structure-Activity Relationship Studies of Hydroxamic Acids as Matrix Metalloproteinase Inhibitors. , 2013, , 71-98.		0
1208	Gene Expression Patterns of Oligodendrocyte Progenitor Cells and Oligodendroglia. , 2013, , .		0
1209	Epigenetics in Castration Resistant Prostate Cancer. Current Clinical Urology, 2014, , 277-295.	0.0	1
1210	Histone Deacetylase Inhibitors As Potential Therapeutic Agents For Various Disorders. Journal of Pharmaceutical Technology Research and Management, 2017, 5, 235-253.	0.2	0
1211	Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 1543-1557.	1.7	5
1212	Gastrointestinal Disasters of Cetuximab in the Treatment of Metastatic Colorectal Cancer: Mechanism and its Effect on Prognosis. Aging Pathobiology and Therapeutics, 2020, 2, 64-72.	0.5	0
1214	Intranasal curcumin and sodium butyrate modulates airway inflammation and fibrosis via HDAC inhibition in allergic asthma. Cytokine, 2022, 149, 155720.	3.2	24
1215	Transcriptional and epigenetic regulatory mechanisms in glioblastoma stem cells. , 2020, , 231-255.		1

#	ARTICLE	IF	CITATIONS
1216	Nghiên cứu tƣng tá»c vớ»i enzyme HDAC8 (1T67) bá»ng Autodock. Tap Chi Khoa Hoc = Journal of Science, 2020, 56, 77.	0.1	0
1217	Nano-Assembly of Quisinostat and Biodegradable Macromolecular Carrier Results in Supramolecular Complexes with Slow-Release Capabilities. <i>Pharmaceutics</i> , 2021, 13, 1834.	4.5	2
1219	New therapeutic approaches: anti-angiogenesis, immunotherapy. , 0, , 247-253.		0
1220	Differentiation Agents and Epigenomic Therapies. , 2007, , 411-443.		0
1221	Chromatin, DNA methylation and neuron gene regulation--the purpose of the package. <i>Journal of Psychiatry and Neuroscience</i> , 2005, 30, 257-63.	2.4	21
1222	Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. <i>Experimental Biology and Medicine</i> , 2007, 232, 227-34.	2.4	183
1223	Histone deacetylase inhibitors as novel anticancer therapeutics. <i>Current Oncology</i> , 2008, 15, 237-43.	2.2	63
1225	Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. <i>American Journal of Translational Research (discontinued)</i> , 2011, 3, 166-79.	0.0	291
1226	Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation. <i>Transactions of the American Clinical and Climatological Association</i> , 2013, 124, 152-62.	0.5	2
1228	Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. <i>Anticancer Research</i> , 2011, 31, 1093-103.	1.1	35
1229	Histone acetyltransferase inhibitor C646 reverses epithelial to mesenchymal transition of human peritoneal mesothelial cells via blocking TGF- β 1/Smad3 signaling pathway in vitro. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 2746-54.	0.5	20
1231	Molecular basis of differentiation therapy for soft tissue sarcomas. <i>Trends in Cancer Research</i> , 2010, 6, 69-90.	1.6	6
1232	Dual role of GRK5 in cancer development and progression. <i>Translational Medicine @ UniSa</i> , 2016, 14, 28-37.	0.5	13
1233	Pharmacotherapy of Gaucher Disease: Current and Future Options. <i>P and T</i> , 2018, 43, 274-309.	0.9	5
1234	Effect of Sodium Butyrate on mRNA Expression as a Transcription Factor of HDAC8 in Human Colorectal Cancer Cell Lines. <i>Avicenna Journal of Medical Biotechnology</i> , 2019, 11, 317-324.	0.3	5
1235	Effect of sodium butyrate on HDAC8 mRNA expression in colorectal cancer cell lines and molecular docking study of LHX1 - sodium butyrate interaction. <i>EXCLI Journal</i> , 2020, 19, 1038-1051.	0.7	1
1236	The protective role of short-chain fatty acids acting as signal molecules in chemotherapy- or radiation-induced intestinal inflammation. <i>American Journal of Cancer Research</i> , 2020, 10, 3508-3531.	1.4	4
1237	Nutrigenetics and nutrigenomicsâ”A personalized approach to nutrition. <i>Advances in Genetics</i> , 2021, 108, 277-340.	1.8	5

#	ARTICLE	IF	CITATIONS
1238	NIR light-controlled mitochondria-targeted delivery of carbon monoxide combined with histone deacetylase inhibition for synergistic anticancer therapy. <i>Journal of Inorganic Biochemistry</i> , 2022, 226, 111656.	3.5	4
1239	Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy. <i>Cells</i> , 2021, 10, 3348.	4.1	30
1240	PEGylated Poly ϵ -HDACi: a Designer Polyprodrug from Optimized Drug Units. <i>Chemistry - A European Journal</i> , 2021, 28, e202103114.	3.3	0
1241	Translational Clinical Strategies for the Prevention of Gastrointestinal Tract Graft Versus Host Disease. <i>Frontiers in Immunology</i> , 2021, 12, 779076.	4.8	2
1242	From natural products to HDAC inhibitors: An overview of drug discovery and design strategy. <i>Biorganic and Medicinal Chemistry</i> , 2021, 52, 116510.	3.0	21
1243	Systematic Review of Gossypol/AT-101 in Cancer Clinical Trials. <i>Pharmaceuticals</i> , 2022, 15, 144.	3.8	21
1244	New Insights Into the Epigenetic Regulation of Inflammatory Bowel Disease. <i>Frontiers in Pharmacology</i> , 2022, 13, 813659.	3.5	18
1245	A Review on Fruit and Vegetable Fermented Beverage-Benefits of Microbes and Beneficial Effects. <i>Food Reviews International</i> , 2023, 39, 4835-4872.	8.4	12
1246	Chromatin alterations during the epididymal maturation of mouse sperm refine the paternally inherited epigenome. <i>Epigenetics and Chromatin</i> , 2022, 15, 2.	3.9	11
1247	Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 781660.	4.8	21
1248	Stimuli responsive self-assembled structural aggregates of ionic liquid based surfactants as the membrane free microreactors for dyes sequestration and drug encapsulation. <i>Journal of Molecular Liquids</i> , 2022, 350, 118555.	4.9	3
1249	Functional oligosaccharide fermentation in the gut: Improving intestinal health and its determinant factors-A review. <i>Carbohydrate Polymers</i> , 2022, 284, 119043.	10.2	34
1250	Butyrate inhibits the bovine rumen epithelial cell proliferation via downregulation of positive regulators at G0/G1 phase checkpoint. <i>Biocell</i> , 2022, 46, 1697-1704.	0.7	1
1251	The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer. <i>Healthcare (Switzerland)</i> , 2022, 10, 557.	2.0	9
1252	Inhibition of class I HDACs preserves hair follicle inductivity in postnatal dermal cells. <i>Scientific Reports</i> , 2021, 11, 24056.	3.3	3
1272	Histone modification enzymes: novel targets for cancer drugs. <i>Expert Opinion on Emerging Drugs</i> , 2004, 9, 135-154.	2.4	29
1274	The Histone Deacetylase Inhibitor I1 Induces Differentiation of Acute Leukemia Cells With MLL Gene Rearrangements via Epigenetic Modification. <i>Frontiers in Pharmacology</i> , 2022, 13, 876076.	3.5	5
1275	Anti-HIV Drug Elvitegravir Suppresses Cancer Metastasis via Increased Proteasomal Degradation of m6A Methyltransferase METTL3. <i>Cancer Research</i> , 2022, 82, 2444-2457.	0.9	39

#	ARTICLE	IF	CITATIONS
1276	Epigenetic modifiers during in vitro maturation as a strategy to increase oocyte competence in bovine. <i>Theriogenology</i> , 2022, 187, 95-101.	2.1	4
1277	Changes in fermentation profile of the reticulorumen and hindgut, and nutrient digestion in dry cows fed concentrate-rich diets supplemented with a phyto-genic feed additive. <i>Journal of Dairy Science</i> , 2022, , .	3.4	4
1278	Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8. <i>European Journal of Medicinal Chemistry</i> , 2022, 239, 114544.	5.5	14
1279	Short-Chain Fatty Acids in the Metabolism of Heart Failure – Rethinking the Fat Stigma. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	18
1280	The potential role of prebiotics, probiotics, and synbiotics in adjuvant cancer therapy especially colorectal cancer. <i>Journal of Food Biochemistry</i> , 2022, 46, .	2.9	9
1281	Synthesis, structure activity relationship and biological evaluation of a novel series of quinoline-based benzamide derivatives as anticancer agents and histone deacetylase (HDAC) inhibitors. <i>Journal of Molecular Structure</i> , 2022, 1267, 133599.	3.6	7
1282	Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	9
1283	Microbiota-derived short-chain fatty acids: Implications for cardiovascular and metabolic disease. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	24
1284	Quantitative Acetylomics Uncover Acetylation-Mediated Pathway Changes Following Histone Deacetylase Inhibition in Anaplastic Large Cell Lymphoma. <i>Cells</i> , 2022, 11, 2380.	4.1	2
1285	Insight into the molecular mechanism of action of anticancer drugs. , 2023, , 477-502.		0
1286	Metabolic Alterations of Short-Chain Fatty Acids and TCA Cycle Intermediates in Human Plasma from Patients with Gastric Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1287	Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	3.5	9
1288	Metabolic alterations of short-chain fatty acids and TCA cycle intermediates in human plasma from patients with gastric cancer. <i>Life Sciences</i> , 2022, 309, 121010.	4.3	10
1289	Pharmacophore-based virtual screening of ZINC database, molecular modeling and designing new derivatives as potential HDAC6 inhibitors. <i>Molecular Diversity</i> , 0, , .	3.9	1
1290	LC-MS Based Lipidomics Depict Phosphatidylethanolamine as Biomarkers of TNBC MDA-MB-231 over nTNBC MCF-7 Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12074.	4.1	5
1291	Bioinformatics analysis of prognostic value and immunological role of MeCP2 in pan-cancer. <i>Scientific Reports</i> , 2022, 12, .	3.3	0
1292	Emergence of nutrigenomics and dietary components as a complementary therapy in cancer prevention. <i>Environmental Science and Pollution Research</i> , 0, , .	5.3	3
1293	Epigenetic alterations fuel brain metastasis via regulating inflammatory cascade. <i>Seminars in Cell and Developmental Biology</i> , 2022, , .	5.0	1

#	ARTICLE	IF	CITATIONS
1294	Myeloid-derived suppressor cell: A crucial player in autoimmune diseases. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
1295	Clinical Utility of Azacitidine in the Management of Acute Myeloid Leukemia: Update on Patient Selection and Reported Outcomes. <i>Cancer Management and Research</i> , 0, Volume 14, 3527-3538.	1.9	1
1296	Self-Healable, Injectable, and Conductive Supramolecular Eutectogel for the Encapsulation and Sustained Release of the Anticancer Drug Curcumin. , 2023, 1, 380-393.		9
1297	Curriculum vitae of HDAC6 in solid tumors. <i>International Journal of Biological Macromolecules</i> , 2023, 230, 123219.	7.5	9
1298	Gut-brain axis. , 2023, , 445-495.		0
1299	HDAC inhibition in cancer. , 2023, , 63-97.		0
1300	Polyphosphazenesâ€”A Promising Candidate for Drug Delivery, Bioimaging, and Tissue Engineering: A Review. <i>Macromolecular Materials and Engineering</i> , 2023, 308, .	3.6	6
1301	Evolution of wound-activated regeneration pathways in the plant kingdom. <i>European Journal of Cell Biology</i> , 2023, 102, 151291.	3.6	4
1302	Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RAR α . <i>Cell Death and Differentiation</i> , 2023, 30, 1320-1333.	11.2	2
1303	Machine learning empowered multi-stress level electromechanical phenotyping for high-dimensional single cell analysis. <i>Biosensors and Bioelectronics</i> , 2023, 225, 115086.	10.1	10
1304	Endocannabinoids are potential inhibitors of glioblastoma multiforme proliferation. <i>Journal of Integrative Medicine</i> , 2023, 21, 120-129.	3.1	1
1305	The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases. <i>Gastroenterology</i> , 2023, 164, 1069-1085.	1.3	14
1306	Cancer Epigenetics. , 2023, , 177-204.		0
1307	The role of viruses in cancer development versus cancer therapy: An oncological perspective. <i>Cancer Medicine</i> , 2023, 12, 11127-11148.	2.8	4
1308	Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	6
1309	30th Annual GP2A Medicinal Chemistry Conference. <i>Pharmaceuticals</i> , 2023, 16, 432.	3.8	0
1310	The Epigenesis of Salivary Glands Carcinoma: From Field Cancerization to Carcinogenesis. <i>Cancers</i> , 2023, 15, 2111.	3.7	3
1311	Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from <i>1,2,3,4-tetrahydroquinoline</i> -elemene scaffold. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2023, 38, .	5.2	2

#	ARTICLE	IF	CITATIONS
1312	Two birds with one stone: Multifunctional ionic liquid based polymeric hydrogel as decontaminant and vehicle for drug delivery. <i>Journal of Molecular Liquids</i> , 2023, 382, 121857.	4.9	3
1313	Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat. <i>Tomography</i> , 2023, 9, 942-954.	1.8	2
1314	The Impact of Histone Modifications in Endometriosis Highlights New Therapeutic Opportunities. <i>Cells</i> , 2023, 12, 1227.	4.1	2
1315	Potential Chemopreventive Role of Pterostilbene in Its Modulation of the Apoptosis Pathway. <i>International Journal of Molecular Sciences</i> , 2023, 24, 9707.	4.1	1
1316	Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies. <i>Cancers</i> , 2023, 15, 2808.	3.7	4
1318	Epigenetic drugs as new emerging therapeutics: What is the scale's orientation of application and challenges?. <i>Pathology Research and Practice</i> , 2023, 248, 154688.	2.3	2
1319	Insights of Indole: A Novel Target in Medicinal Chemistry (A Review). <i>Russian Journal of General Chemistry</i> , 2023, 93, 1791-1841.	0.8	1
1320	Meat and Alcohol Consumption: Diet and Lifestyle Choice and Cancer. , 2023, , 105-117.		0
1321	The associations between dietary fibers intake and systemic immune and inflammatory biomarkers, a multi-cycle study of NHANES 2015â€“2020. <i>Frontiers in Nutrition</i> , 0, 10, .	3.7	2
1322	Untargeted LC-MS/MS Metabolomics Study of HO-AAVPA and VPA on Breast Cancer Cell Lines. <i>International Journal of Molecular Sciences</i> , 2023, 24, 14543.	4.1	0
1323	A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance. <i>Acta Pharmaceutica Sinica B</i> , 2024, 14, 223-240.	12.0	2
1324	Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkinâ€™s Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen. <i>Acta Haematologica</i> , 0, , 1-9.	1.4	0
1325	HDAC1: An Essential and Conserved Member of the Diverse Zn ²⁺ -Dependent HDAC Family Driven by Divergent Selection Pressure. <i>International Journal of Molecular Sciences</i> , 2023, 24, 17072.	4.1	0
1326	Genome-wide CRISPR/Cas9 knockout screening to mitigate cell growth inhibition induced by histone deacetylase inhibitors in recombinant CHO cells. <i>Biotechnology and Bioengineering</i> , 2024, 121, 931-941.	3.3	0
1327	Genetics, Nutrition, and Health: A New Frontier in Disease Prevention. , 0, , 1-13.		0
1328	Reprogramming of Primed Human Pluripotent Stem Cells into a Na ⁺ -ve State. <i>Russian Journal of Developmental Biology</i> , 2023, 54, 217-232.	0.5	0
1329	Nutrition and Epigenetic. <i>TÃ¼rkiye SaÄŸliÄ±k Bilimleri Ve AraÅŸtarmalar Dergisi</i> , 0, , 104-120.	0.5	0
1330	Deep Eutectic Solvent and Poly (Vinyl Alcohol) Based Self-Healable, Injectable and Adhesive â€œEutectogelâ€• An Emerging Drug Delivery Vehicle. <i>ChemistrySelect</i> , 2024, 9, .	1.5	0

#	ARTICLE	IF	CITATIONS
1331	Fission Yeast-based Screening to Identify Putative HDAC Inhibitors Using a Telomeric Reporter Strain. <i>Molecules and Cells</i> , 2008, 26, 93-99.	2.6	0
1332	Epigenetic changes in shear-stressed endothelial cells. <i>Cell Biology International</i> , 2024, 48, 665-681.	3.0	0
1333	Krebsepigenetik. , 2024, , 205-237.		0
1334	Preliminary Exposure to Histone Deacetylase Inhibitors Changes the Direction of Human iPSCs™ Differentiation with the Formation of Cardiospheres Instead of Skin Organoids. <i>Russian Journal of Developmental Biology</i> , 2023, 54, 350-357.	0.5	0
1335	Short-Chain Fatty Acid (SCFA) as a Connecting Link between Microbiota and Gut-Lung Axis – A Potential Therapeutic Intervention to Improve Lung Health. <i>ACS Omega</i> , 2024, 9, 14648-14671.	3.5	0